 
 
 
 
Protocol : I8B-MC-ITSZ(b)  
 
 
An Exploratory Study Assessing Time in Target Glucose Range Using a New  
Titration Scheme of LY900014 and Insulin Degludec in Participants with Type 
1 Diabetes  
 
 
[STUDY_ID_REMOVED]  
 
 
Approval Date: 24- Nov-2020  
CONFIDENTIAL I8B-MC-ITSZ (b)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of LY900014 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.
Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.
Protocol Title: An Exploratory Study Assess ingTime in Target Glucose Range Using a New
Titration Scheme of LY900014 and Insulin Degludec in Participants with Type 1 
Diabetes
Protocol Number: I8B-MC-ITSZ
Amendment Number: (b)
Compound :LY900014
Study Phase: Phase 2
Short Title: Dose optimizat ion study
Acronym :ITSZ
Sponsor Name: Eli Lilly  and Com pany
Legal Registered Address: Indianapo lis, Indiana ,USA 46285
Regulatory Agency Identifier Number(s)
IND: 127210
Approval Date: Protocol Amendment (b) Electronically Signed and Approved by Lilly  on date 
provi ded below.
Approval Date: 24-Nov-2020 GMT
CONFIDENTIAL I8B-MC-ITSZ (b)
2Medical Monitor Name and Contact Information will be provided separately.
CONFIDENTIAL I8B-MC-ITSZ (b)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment (a) 12-Jul-2020
Original p rotocol I8B-MC -ITSZ 08-Jun-2020
Amendment [b] 
Overall Rationale for the Amendment:
The main purpose of this protocol amendment i s to modify the inclusi on criteria related to the 
type of rapi d-acting insulin analog and the CGM system used at study  entry . 
Section # and Name Description of Change Brief Rationale
1.3 Schedule of Activities 
(SoA) , 4.1.1 Study  visitsUpdate dlanguage regarding use of 
personal CGM system at Visit 13Clarification based on anupdate to inclusion 
criterion #12
1.3 Schedule of Activities 
(SoA) , 4.1.1 Study  visitsUpdate dthe note thatparticipants 
who enter the study on Novolog, 
Admelog, or Apidr awill transition 
to Humalog at Visit 2Clarification based on anupdate to inclusion 
criterion # 6
5 Study  population Updated language regarding type of
rapid -acting insulin analog usedClarification based on an update to inclusion 
criterion #6
5.1 Inclusion Criteria Update dcriterion #6 regarding the 
typesof rapid -acting insulin analog
usedTo update criterion to include Admelog and
Apidra as rapid -acting insulin analog used
5.1 Inclusion Criteria Update dcriterion #12 to clarify the 
use of CGM systemTo update criterion to include unblinded 
personal CGM use of at least 2 months in 
the prior 6 months
8.3 Adverse events and 
serious adverse eventsRem oved the term ‘legally 
autho rized representative ’To remove the term ‘legally autho rized
representative’ as only study  participant s
can provide informed consent
Appendix 10.1.3 Update dsection regarding informed 
consent processTo remove the term ‘legally autho rized
representative ’as only study  participant s
canprovide informed consent
Throughout Minor editorial and document 
formatting revisionsThese are minor changes; therefore, they 
have not been summarized
CONFIDENTIAL I8B-MC-ITSZ (b)
4Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ......................................................................................................................... 8
1.3. Schedule of Act ivities (SoA) ........................................................................................ 9
2. Introduction .............................................................................................................. 19
2.1. Study  Rati onale .......................................................................................................... 19
2.2. Backgro und................................................................................................................ 20
2.3. Benefit -Risk Assessment ............................................................................................ 22
2.3.1. Risk Assessment ......................................................................................................... 23
2.3.2. Benefit Assessment ..................................................................................................... 25
2.3.3. Overall Benefit: Risk Conclusio n................................................................................ 25
3. Objectives and Endpoints ......................................................................................... 26
4. Study Design ............................................................................................................. 28
4.1. Overall Desig n............................................................................................................ 28
4.1.1. Study  Visi ts................................................................................................................ 28
4.2. Scientific Rationale for Study  Design ......................................................................... 32
4.3. Justification for Dose .................................................................................................. 32
4.3.1. Target Gl ucose Val ues f or Ti tration of  Insulin Therapy .............................................. 33
4.3.2. LY900014 .................................................................................................................. 33
4.3.3. Insulin Degludec ......................................................................................................... 34
4.4. End of Study  Definit ion.............................................................................................. 34
5. Study Population ...................................................................................................... 35
5.1. Inclusio n Cri teria........................................................................................................ 35
5.2. Exclusio n Cri teria....................................................................................................... 37
5.3. Lifes tyle Considerat ions............................................................................................. 39
5.3.1. Meals and Dietary  Restri ctions................................................................................... 40
5.3.2. Activity...................................................................................................................... 40
5.4. Screen Failures ........................................................................................................... 40
6. Study Int ervention .................................................................................................... 41
6.1. Study  Intervent ion(s) Administered ............................................................................ 41
6.1.1. Medical Devices ......................................................................................................... 41
6.2. Prepa ration/Handling/Storage/Accountabilit y............................................................. 42
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 42
6.4. Study  Intervent ion Compliance ................................................................................... 42
6.5. Concomitant Therapy .................................................................................................42
6.6. Dose Modificat ion...................................................................................................... 43
6.7. Intervention after the End of the Study ........................................................................ 43
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 44
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 44
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 44
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 45
CONFIDENTIAL I8B-MC-ITSZ (b)
57.3. Lost to Follow -up....................................................................................................... 45
8. Study Assessments and Procedures ......................................................................... 46
8.1. Efficacy Assessments .................................................................................................46
8.1.1. Primary Efficacy  Assessments .................................................................................... 46
8.1.2. Secondary  Efficacy  Assessments ................................................................................ 46
8.2. Safety Assessments .................................................................................................... 46
8.2.1. Physical Examinat ions................................................................................................ 46
8.2.2. Vital Signs.................................................................................................................. 46
8.2.3. Electrocardiograms ..................................................................................................... 47
8.2.4. Clinical Safety  Laboratory  Assessments ..................................................................... 47
8.2.5. Self-monitoring o f Blood Gl ucose .............................................................................. 47
8.2.6. Hypoglycemia ............................................................................................................ 47
8.2.7. Safety Moni toring ....................................................................................................... 48
8.3. Adverse Events and Serious Adverse Events .............................................................. 49
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 49
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 49
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 49
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 50
8.3.5. Pregnancy ................................................................................................................... 50
8.3.6. Adverse Events of Special Interest .............................................................................. 50
8.3.7. Product Complaint s.................................................................................................... 50
8.4. Treatment of Overdose ............................................................................................... 51
8.5. Pharmacokinet ics........................................................................................................ 51
8.6. Pharmac odynamics ..................................................................................................... 51
8.7. Genet ics..................................................................................................................... 51
8.8. Biomarkers ................................................................................................................. 51
8.9. Immunogenicit y Assessments ..................................................................................... 51
8.10. Health Economics ....................................................................................................... 52
9. Statistical Considerations ......................................................................................... 53
9.1. Statistical Hypotheses .................................................................................................53
9.2. Sample Si ze Determinat ion......................................................................................... 53
9.3. Popul ations for Analyses ............................................................................................ 53
9.4. Statistical Analyses ..................................................................................................... 53
9.4.1. General Considerations ............................................................................................... 53
9.4.2. Primary Endpo int(s)................................................................................................... 54
9.4.3. Secondary  Endpo int(s)................................................................................................ 55
9.4.4. Exploratory  Endpo ints................................................................................................ 55
9.4.5. Other Safet y Analyses ................................................................................................ 55
9.4.6. Other Analyses ........................................................................................................... 55
9.5. Interim Analyses ......................................................................................................... 56
9.6. Data Monitoring Committee ....................................................................................... 56
10. Supporting Documentation and Operational Considerations ................................ 57
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 57
CONFIDENTIAL I8B-MC-ITSZ (b)
610.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 57
10.1.2. Financial Disclo sure................................................................................................... 57
10.1.3. Inform ed Consent Process .......................................................................................... 58
10.1.4. Data Protection ........................................................................................................... 58
10.1.5. Disseminat ion of Clinical Study  Data ......................................................................... 58
10.1.6. Data Qualit y Assurance .............................................................................................. 59
10.1.7. Source Documents ...................................................................................................... 60
10.1.8. Study  and Si te and Cl osure ......................................................................................... 60
10.1.9. Publicat ion Policy ....................................................................................................... 61
10.1.10. Invest igator Informat ion............................................................................................. 61
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 62
10.2.1. Hypersensi tivity Clinical Laboratory  Tests .................................................................63
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 65
10.3.1. Definit ion of AE......................................................................................................... 65
10.3.2. Definit ion of SAE ....................................................................................................... 66
10.3.3. Recording and Fo llow-up of  AE and/or SAE .............................................................. 67
10.3.4. Reporting of SAEs ...................................................................................................... 69
10.4. Appendix 4: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 70
10.5. Appendix 5: Hepatic Safet y: Suggested Actions and Follow -up 
Assessments ............................................................................................................... 73
10.5.1. Hepati c Evaluat ion Testing ......................................................................................... 75
10.6. Appendix 9: Abbreviat ions......................................................................................... 77
10.7. Appendix 10: Protocol Amendment History ............................................................... 81
11. References ................................................................................................................. 82
CONFIDENTIAL I8B-MC-ITSZ (b)
71. Protocol Summary
1.1. Synopsis
Protocol Title: An exploratory study  assess ingtime in target glucose range using a new titration 
scheme of LY900014 and insulin degludec in pa rticipants with Type 1 Di abetes
Short Title: Dose Optimizat ionstudy
Rationale :In clinical pract ice, prandi al insulins are often ti trated based on ‘next pre -meal 
glucose’ . For example, clinicians use the pre-lunchblood glucose value to assess the adequacy of 
the breakfast prandial dose. This co mmo nly used titration scheme may not be fully optimized for 
the novel t ime-action profile o f LY900014. An alternate approach of using peak post -prandial 
glucose (PPG) val uesor the change fro m pre-meal levels may be better -suited to ti trating ultra -
rapid acting prandial insulins. In particular, the ‘faster on -faster off’ profile o f LY900014 might 
allow more aggressive prandial dosing that would further improve PPG without inc reasing the 
risk of late post -meal hypoglycemia .
The aim of this study  is toevaluate the percentage of time with glucose values within target 
range (70 to 180 mg/dL, both inclusive) after 35 days of using a new titration scheme wit h 
LY900014 treatment and degludec.
Objectives and Endpoint s
Objectives Endpoints
Primary
To evaluate the time thatglucose values are 
within the target range 70 to 180 mg/dL from 
CGM use, after 35 day s of using the study
titration scheme wi th LY900014 treatment and 
degludecPercentage of time with sensor glucose 
values between 70 and 180 mg/dL (both 
inclusive), with CGM use during the 
maintenance period
Secondary
To evaluate ICR with LY900014 treatment ICR at the end of the maintenance period
To evaluate the relationship between ICR and 
TDD with LY900014 treatmentICR×TDD forthe maintenance peri od
To evaluate total daily, basal, and prandial 
insulin dose with LY900014 treatment and 
degludecPrandial: TDD rati o forthe maintenance 
period
Abbreviations: CGM = continuous glucose monitoring; ICR = insulin -to-carboh ydrate ratio ; TDD = Total Daily 
Dose .
CONFIDENTIAL I8B-MC-ITSZ (b)
8Overall Design
Study  I8B-MC-ITSZ (ITSZ) i s a multicenter, single- group , open- label, Phase 2 study  that will be 
conducted in pa rticipants with type 1 diabetes (T1D) currently treated with insulin degludec and 
a rapid -acting insulin analog in a multiple daily injection (MDI )regimen. The object ive of the 
study  is to assess the percentage of time glucose values are within the target range of70 to 180 
mg/dL after 35 days of ti tration using the study titration scheme of LY900014 and insulin 
degludec in pa rticipants with type 1 diabetes .
Disclosure Statement : This is a single treatment group study  with no m asking.
Number of Participants
Approximately 34 participants will be assigned to study  treatm ent intervent ion such that 
approximately  30evaluable participants complete the study . 
Intervention Groups and Duration
The total  durati on of  study  parti cipati on for each parti cipant is approxim ately 74days across the 
following study  periods:
Screening ,up to 1 0days
Lead in period, 11 days
Treatment period
oTitration peri od, 35 day s
oMaintenance period, 1 1days
Safety follow-upperiod, 7days
Data Monitoring Committee: 
No.
1.2. Schema
T =Telephone visit s

CONFIDENTIAL I8B-MC-ITSZ (b)
91.3. Schedule of Activities (SoA)
Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
Telepho ne visits are indicated by shaded columns. Telephone visits can become office visits. Site documentation will serve as the source for telephone visits.
Informed Consent 
SignedX
Participa nt eligibility 
reviewX X
IWRS X X X X X X X X X X X X X X X
Clinical Assessments
Participa nt demographics X
Medical history and 
preexisting conditionsX
Physical exam . /height X
Body Weight X X X X X X
Note: Participa nts should be advised to remove their shoes/coats and empty their pockets before the body weight is obtained .
CONFIDENTIAL I8B-MC-ITSZ (b)
10Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
Vital signs
blood pressure and heart 
rateX X X X X X
Note: Vital sign measurements should be determined after pa rticipa nts have been seated quietly for at least 5 minutes in a chair with 
feet on the floor. The arm used for blood pressure measurement should be supported at heart level
ECG (12 -lead, local) X
Participa nts must be supine for approximately 5 to 10 minutes before ECG collection and remain supine, but awake, during ECG 
collection.
Concomitant medications X X X X X X X X X X X X X X X X
Adverse events and 
product complaintsX X X X X X X X X X X X X X X X
CONFIDENTIAL I8B-MC-ITSZ (b)
11Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
Participant Education and Management
Diabetes education and 
nutritio n counselingX
Note: Diabetes education and nutrition counseling may be offered at additional visits if necessary. 
Confirmation of 
minimum baseline CGM 
data from SMS portal 
available before
treatment assignmentX
Note: Investigator staff should determine before Visit 3 from the participant’s Data Acceptability Report in the SMS portal that the 
participant will meet the minimum CGM requirements. The investigator should communicate to the participant whether h e or she 
has met the minimum CGM requirements before treatment assignment at Visit 3 . See Section 4.1.1 under Lead in period “CGM” 
for how to determine the minimum requir ements.
Treatment assignment X
Switch to morning 
administration of insulin 
degludec if applicableX
Review ambulatory 
glucose profile using X X X X X X X X X X X X X X
CONFIDENTIAL I8B-MC-ITSZ (b)
12Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
CGM data in Clarity
Print InPen report and 
review insulin doses. 
Retain InPen report as a 
part of the pa rticipa nt’s 
medical chartXX X X X X X X X X X X X
Note: The investigator should confirm thereceipt of the InPen report before each study visit. 
Keep degludec insulin 
dose, ICR, ISF , and DIA
unchanged unless for 
safety reasonsX X X
Note: Insulin dose, ICR, ISF , and DIA should remain unchanged during the screening, lead -in, and maintenance period unless for 
safety reasons. At the end of the maintenance period (Visit 14 ), the investigator may adjust the participant’s ICR to the value he or 
she had at study entry. 
Adjust DIA as needed XX X X X X X X X X X
Note: The investigator is not required to adjust the DIA. However, if dose and CGM data indicate that a different duration of insulin 
action is necessary for participant safety or for optimizing glycemic control, the investigator should make the necessary cha nges. 
Adjust both basal and 
bolus insulin doses, IC R, 
and ISF as needed to 
achieve glucose targetXX X X X X X X X X X
Note: Please refer to Section 4.3of the protocol for more details.
CONFIDENTIAL I8B-MC-ITSZ (b)
13Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
Start non -study rapid -
acting insulin analogX X
Remind participant to 
bring their personal 
CGM system to Visit 14X
Participants return to 
their personal CGM 
deviceX X
Devices, Supplies, and IP
Dispense CGM supplies X X X
Ensure that CGM mobile 
application is installed on 
participant’s smart 
phone. Ensure 
participants activate and 
set up their accountX
Grant site permission to 
access participant dataX
Note: The investigator should check the participant’s eligibility before they request access to participant data in CLARITY. 
CONFIDENTIAL I8B-MC-ITSZ (b)
14Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
from CLARITY
CGM training X
Note: Additional CGM training may be performed as needed.
Start Sponsor provided 
CGM sensor session X
Note: See Section 4.1.1 for details. 
Dispense InPen and 
associated suppliesX
Download InPen mobile 
app o n smart phone. 
Ensure participants 
activate and set up their 
InPen accountX
Note: Smartphone encompasses Android and Apple iPhone with compatible operating system .
InPen training X
Note: Additional InPen training may be perfo rmed as needed.
All participants X
CONFIDENTIAL I8B-MC-ITSZ (b)
15Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
administer Humalog as 
rapid -acting insulin with 
the InPen during the lead 
in periodNote: Participants entering the study on Novolog , Admelog, or Apidra will transition to Humalog.
Remind participant of 
required actions and 
study procedure with 
InPen and CGMX X X X X X X X X X X X
Note: The investigator should remind the pa rticipa nt of the following things:
LY900014 should be administered 0 -2 minutes before the start of each meal and snack (not applicable for Visit 2) .
InPen reports should be sent before each visit .
Mealtime anddegludec dose should be entered into the Dexcom mobile app for Day s -10 to -1 and Days 36 to 45 .
Dispense ancillary 
suppliesX
Dispense IP X X
Dispense pharmacy cards X
Note: Participants will use pharmacy card to obtain Humalog 3 mL cartridge for us ewith the InPen during the lead -in period .
Participa nt returns 
unused study drug X X X X
CONFIDENTIAL I8B-MC-ITSZ (b)
16Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
Participant returns InPen 
device and associated 
suppliesX X
Participant returns 
provided unused 
Dexcom G6 supplies to 
siteX X
Rem ove access to 
participa nt’s CLARITY 
account and SMS portalX X
Note: If an investigator is the participant’s primary care provider, the investigator may discuss with the participant whether they 
would like to retain the link to the CLARITY account .
Drug accountability X X X X X
Transfer data into eCRF
Transcribe requested 
data into eCRF from 
participa nt’s medical 
chartX X X X X X X X X X X X X X
Note: The following data are requested: ICR, ISF ,and DIA from the day before visit.
Transcribe requested X X X
CONFIDENTIAL I8B-MC-ITSZ (b)
17Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
data into eCRF from 
InPen pdf report from 
each day of the lead in 
period ( Days -10 to -1) 
and f rom the 
maintenance period 
(Days 36 to 45)Note :Individual Humalog doses from each day during the lead-inperiod and LY900014 doses during the maintenance period are
requested .
Laboratory Assessments
HbA1c X X
Fructosamine X X
1,5 AG X X
Hematology X
Chemistry panel X
Urinaly sis X
Serum Pregnancy test X
Note: Serum pregnancy test must be performed in women of childbearing potential at Visit 1 and at other times at the investigator’s 
CONFIDENTIAL I8B-MC-ITSZ (b)
18Screen Lead in 
Period
-11 to 
-1Treatment Period Safety 
Follow-
upET
Titration Period
Days0 to 35Maintenance
Days36 to 
46Days 47
to 53
Day -21to
-12-11 0 3 7 10 14 17 21 24 28 31 35 46 53 ET
Visit Window (days) 0 +/-3 +3-1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 -1/+2 +3 +/-3
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 801 ET
discretio n.
Urine Pregnancy test X
Note: A urine pregnancy test must be performed in women of childbearing potential within 24 hours before IP exposure at Visit 3 
and w hen required per local regulations and/or institutional guidelines, local pregnancy testing will occur at mandatory time s during 
the study  treatment period .
Follicle stimulating 
hormone testX
Note: Follicle -stimulating hormone test must be performed at Visit 1 for a post -menopausal woman who is at least 40 years of age 
with an intact uterus, not on hormone therapy, and who has had cessation of menses for at least 1 year without an alternative 
medical cause .
Abbreviations: AG = anhydroglucitol ; CGM = continuous glucose monitoring ; DIA = Duration of Insulin Action ; ECG = electrocardiogram ; eCRF = electronic 
case report form ; ET = Early  Termination; HbA1c = hemoglobin A1c ; ICR = insulin -to-carbohydrate ratio ; IP = investigational product ; ISF = insulin 
sensitivity factor ; IWRS = interactive web -response sy stem ; SMS = Study management suite.
CONFIDENTIAL I8B-MC-ITSZ (b)
192. Introduction
LY900014 is an ultra -rapid-acting formulationof insulin lispro developed by Eli Lilly  and 
Company (Lilly ) for subcutaneous (SC) use and for intravenous (IV) use to improve glycemic 
control  in participants with type 1 di abetes m ellitus (T1D) or ty pe 2 diabetes mellitus (T2D).
2.1. Study Rationale
Rapid-acting insulin analogshave been shown to have a more rapid onset of action co mpared 
with human insulin . However, the consensus is that they are not rapid enough to match
carbohydrate absorption and many  patients are unable to achieve optimal glycemic control.
An ultra -rapid-acting prandial insulin that would shift the pharmacokinetic (PK) and 
pharmacodynamic (PD) profiles of insulin to provide an even faster onset of actio n woul d better 
match carbohydrate absorption and allow for efficacious dosing immediately  beforemeals. An 
ultra-rapid insulin would be useful in the treatment of T1D andT2D when delivered by MDI, 
continuous subcutaneous insulin infusio n, or in clo sed loop and hybrid closed loop automated 
insulin delivery  systems.
An ultra -rapidtime- action profile has been achieved for LY900014 through the addit ion of 2 
novel excipients : microdoses of treprostinil, a prostacy clin anal og th at increases local capillary 
blood flow ,andcitrate, whi chenhance svascular permeabilit y.The Phase 3 PRONTO studiesin 
patients wi th T1D and T2D on MDI regimens demonstrated that LY900014 was noninferior to 
Hum alog inhemoglo bin A1c (HbA1c )reducti onwhen administered as prandial insulin in 
combinat ion with basal insulin for 26 weeks (Klaff et al. 2019) ( Blevins et al 2019). LY900014 
also demonstrated superior ityto Hum alog in controlling 1 -hour and 2- hour PPG excursions 
during mixed -meal tolerance te sts in both patients with T1D and T2D . Improved time in range 
during day time was observed in patients with T1D treated wi th LY900014.
In the PRONTO Diabetes studi es, using individualized dose titration, mean bo lus:basal insulin 
dose ratios at study  endpo intswere approximately 50:50 in both patients with T1D and T2D, 
which are ty pical for intensive insulin regimens. The design of the PRONTO Diabetes studi es 
included an 8- week basal insulin optimization period in combinat ion with prandial lispro before
rando mizat ion, which might have favoredaggressive titration of the basal insulin and likely 
limited titration of LY900014 and Humalog during the subsequent treatment period ,as the mean 
HbA1c was 7.3% at the end of the lead -in period. The PRONTO Diabetes studies provide strong 
support for the efficacy  and safet yof LY900014 treatm ent as part of anMDI regimen. Despite 
this, it is possible that patient outcomes could be further optimized with alternate dosing 
regimens .
In clinical pract ice, the dosing form ulas current ly widely used by  clinicians are as follows 
(DeWitt and Hirsch 2003 , Bode 2004 , Pickup 2009):
Total Basal Dose (TBD) =0.5×T otal Daily Dose (TDD)
Insulin -to-Carbohy drate Ratio (ICR)=450~500/TDD (“450 Rule” or “500 Rule”)
Correcti on Factor (CF) =1700~1800/TDD
CONFIDENTIAL I8B-MC-ITSZ (b)
20These formulas originated from C -peptide kinetic studies of insulin secret ion and fro m 
retrospective reviews of pump download in ‘well -controll ed’ pat ients, which have so me 
limitations. For example, TBD=0.5 × TDD came from c -pepti de kinetic studi es of  insulin 
secretions in healt hy vo lunteers and assumed that the basal insulin need is flat and constant 
throughout the entire day (Kruszynska et al. 1987, Polonsky et al. 1988) . Recent prospective 
insulin titration studi es, including studi es using structured professio nal cont inuous glucose 
monitoring (CGM), demonstrate that current dosing formulas reco mmend too high of a dose for 
basal insulin and too low of a dose for bolus insulin (King and Armstrong 2007 a, b, King 2010 , 
Kuroda et al. 2012 ).
Prandial insulins are often t itrated based on ‘next pre -meal glucose’ ( for example, using 
pre-lunch value to assess adequacy  of the breakfast prandial dose). This c ommonly used t itration 
scheme may not be optimized for the novel t ime-action profile of LY900014. An al ternate 
approach ofusing peak post-prandial glucose ( PPG)values or the change from pre -meal levels 
may be better -suited to titrating ultra-rapidacting prandial insulins. In part icular, the ‘faster on -
faster off’ profile of LY900014 might allow more aggressive prandial dosing that would further 
improve PPG without increasing the risk of late post -meal hypoglycemia.
The aim of this study  is to explore a new titration scheme of LY900014 to optimize glycemic 
control , when administered as prandial insulin, in combinat ion with insulin degludec for 35 day s. 
Insulin t itration will be based on real -time Dexco m G6 CGM readings, which are approved by  
theFood and Drug Administration ( FDA )for making clinical decisio ns.
2.2. Backgr ound
Type 1 di abetes is an autoimmune disease mediated by a co mbinat ion of genetic and 
environmental triggers result ing in lymphocy tic infil tration of  pancreat ic islets, destruction of 
beta cells, and lifelo ng dependency on exogenous in sulin. The prevalence of T1D is near 1 in 
300 and its incidence is steadily increasing worldwide (3% per y ear) (Gan et al. 2012]).
There have been many  advances in the treatm ent of T1D in the last 20 y ears; however, reaching 
and maintaining glycemic goals remains challenging even under intensive insulin therapy 
regimens. Only approximately 30% of insulin requiring diabetes pati ents are able to reach the 
goal HbA1c target of <7% ( Stark -Casagrande et al. 2013).
Recent prospective insulin t itration studi esusing structured professio nal cont inuous glucose 
monitoring (CGM) demonstrate that current dosing formulas widely  used in clinical pract ice
prom ote under -dosing of mealt imeinsulin (Kuroda et al. 2012) (King 2012) (King and 
Armstrong 2007 a, b).Using a new titration scheme for LY900014 might further improve 
glycemic control in pat ients with T1D on MDI regimen. 
LY900014
LY900014 is co mposed of the active ingredient, insulin lispro, and 2 enabling excipients 
(treprostinil and citrate) that facilitate rapid absorpti on of  insulin lispro into the blood stream.
This novel formulat ion results in earlier glucose lowering when compared wit h Humalog. This 
faster glucose -lowering response, as demonstrated by the PK and PD profiles of LY900014 when
compared wi th Humal og, m ore cl osely  mimics the time -action profile of normal endogenous 
insulin secret ionand m aybetter match the speed of meal carbohydrate absorption .In previous 
CONFIDENTIAL I8B-MC-ITSZ (b)
21clinical pharmaco logy studi es, LY900014 and Humalog were shown to be equipotent. In the 
completed Phase 3 studies, LY900014 and Humalog subst ituted generally on a uni t-for-unit 
basis; LY900014 and Humalog doses at Week 26 were not statistically significant ly different 
after titration. In addit ion, no si gnificant difference between LY900014 and Humal og were 
observed in pump settings or bolus calculator settings in Phase 3 studies either.
The Investigator’s Brochure (IB) describes the clinical and nonclinical development of 
LY900014. 
InPen™
Com panion Medical’s InPen system  is an FDA -approved class II device for use wi th Hum alog,
Novol og, or Fi asp. Lilly  has determined that LY900014 is suitable for use with the InPen system
under the condit ions of the current invest igational study . The InPen system consists of a 
manually controlled pen injector and an app containing a logbook and a dose (bolus) calculator.
The InPen is a ho me-use reusable pen injector for single -patient use by  peopl e with diabetes 
aged 12 years and ol der for the self -injecti on of  a desi red dose of insulin. The pen injector is 
compatible with Humalog U -100 3.0 m L cartri dges, which have the same dimensio ns to 
LY900014 cartridges, and single -use detachable and disposable pen needles. Cartridges of the 
pen injector allow the user to dial the desired dose fro m 0.5 to 30 units in one- halfunit 
increments.
The InPen app is designed to manage with the InPen injector a wireless transfer of 
insulin dose 
insulin dose time 
mealt ime carbohydrates
time of meal
The InPen app also provide sa dose cal culator to aid bolus insulin dose calculations. Before the 
use of the InPen app dose calculator, a health care professio nal (HCP) must provide the 
participant with specific target blood glucose, insulin -to-carbohydrate ratio, insulin sensit ivity 
param eters ,and durati on of  insulin act ion to be entered into the InPen app .
Dexcom G6
Dexco m G6 CGM System  is a real  time, CGM device indicated for the management of diabetes 
in individuals aged2 years and ol der. Dexco m G6 Sy stem  is an FDA -approved class II device 
that can replace fingerst ick bloo d glucose testing for diabetes treatment decisio ns. 
Dexco m G6 CGM System  has the fo llowing com ponents:
G6 CGM sensor
G6 CGM transmitter
G6 CGM receiver
G6 System  mobile app
The G6 CGM sensor continuously  measures glucose concentration in interst itial fluid and can be 
worn for up to 10 day s. When a new sensor is started, a code m ust be entered into the display  
device to use the G6 without fingerstick calibrat ions. Each sensor has its own code printed on the 
back o f the adhesive patch. Calibrat ion is not req uired if users enter a sensor code. The G6 CGM 
CONFIDENTIAL I8B-MC-ITSZ (b)
22transmitter contains a Bluetooth radio transceiver for communicat ion with a com patible display 
device, either the G6 CGM receiver or a smart device. Parti cipants in Study  ITSZ will be using a 
smart devi ce to receive data fro m the G6 CGM transmitter instead of the G6 CGM receiver. 
The Dexco m G6 System  mobile app is for i OS and Androi d. The m obile app provi des an 
alternat ivedisplay  device to the receiv er for users with compatible smart devices and behaves 
similarly  to the receiver. The user has the abilit y to manually enter insulin dose and insulin dose 
time as well as meal carbohydrates and time into the m obile app. This dosing and meal 
inform ation can also be entered retroactively. 
2.3. Benefit -Risk Assessment
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected adverse events (AEs) of LY900014 m ay be found in the IB.
CONFIDENTIAL I8B-MC-ITSZ (b)
232.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention (s) LY900014
Hypoglycemia
Hyperglycemia
Hypersensitivity and Allergic 
reactions See IB Section 6.2.2.5.1 Each participant will receive Diabetes education and 
counseling on how to avoid the risks of hypoglycemia and 
hyperglycemia at Visit 2.
CGM alerts will be set up during Visit 2 for early detection 
of hy poglycemia and hyperglycemia. Participants with 
known hypersensitivity or allergy to any of the study 
medications or their excipients will be excluded from the 
study. 
Study Procedures
InPen and Mobile medical app (MMA)
Errors of LY900014 dose 
deliveryLY900014 is notapproved to be used with InPen; however,
it isexpected to perform similarly to Humalog due to the 
following reasons:
•InPen is compatible with Humalog U -100 3.0 mL 
cartridges, which have the same dimensions to 
LY900014 cartridges 
•Lilly  has internal data for LY900014 supporting in use 
stability for the container closure and fluid path ( that 
is,needle), which are the same as Humalog 
•LY900014 and Humalog are shown to be equipotent in 
clinical pharmacology studies
•LY900014 and Humalog substituted generally on a 
unit-for-unit basis in clinical pharmacology and Phase 
3 studies
•In the pivotal study of LY900014 in adult patients with 
T1D, Study ITRM, at study endpoint of 26 weeks, 
doses of LY900014 and Humalog were not 
significantly different after titration 
•There were no meaningful difference in safety 
observed between LY900014 and Humalog in Phase 3 
studies (that is, incidence of adverse events and Lilly  has completed preliminary testing of InPen
supporting dose accuracy when used with LY900014 . 
Definitive dose accuracy testing will be completed 
before study initiation
Real-time CGM guided insulin titration with hypo -and 
hyperglycemia alerts set up
Site selection: choose experienced primary 
investigators (PIs) and site staff with LY900014 and 
diabetes technology
Strict monitoring of pa tients through frequent 
interactions with investigator s, who have 24/7 access to 
patient CGM data in CLARITY
Enrollment of technologically -competent and highly 
compliant patients
Careful lyplanned site training and patient training
Based on the medical ris k assessment, potential risks of 
using InPen with LY900014 off -label can be managed 
effectively upon the implementation of risk mitigation 
CONFIDENTIAL I8B-MC-ITSZ (b)
24Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
hypoglycemia)
•There were no clinically meaningful difference 
between L Y900014 and Humalog in pump settings or 
bolus calculator settings (including active insulin time) 
in Phase 3 studiesplans. Lilly Medical concluded that if InPen passes Lilly 
dose accuracy testing with LY900014, InPen can be safely 
used in Study ITSZ due to the expected similar performance 
between LY900014 and Humalog 
Abbreviations: CGM = continuous glucose monitoring; T1D = type 1 diabetes.
CONFIDENTIAL I8B-MC-ITSZ (b)
252.3.2. Benefit Assessment
No di rect clinical benefit is ant icipated fro m participat ing in this trial due to the short nature of 
this study . However, som e parti cipants m ay benefit fromimproved glycemic control as a result 
of the dose ti tration strategy , frequent ICR, I SF, DIA, and insulin dose adjust ments, and 
increased engagement with an HCP. 
More detailed informat ion about the known and expected benefits and ri sks of LY900014 alo ng 
with its clinical and nonclinical devel opment can be found in the IB. 
More detailed informat ion about the known and expected benefits and risks of degludec m ay be 
found in the USPI (Tresiba package insert, 2015) .
2.3.3. Overall Benefit: Risk Conclusion
Considering the measures taken to minimize risk to participants involved in this study , the 
potenti al risks ident ified in associat ion with LY900014 are justified by the potenti al benefits that 
may be afforded to participants with T1D.
CONFIDENTIAL I8B-MC-ITSZ (b)
263. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the time that glucose values are 
within the target range 70 to 180 mg/dL from 
CGM use, after 35 day s of using the study
titration scheme wi th LY900014 treatment and 
degludecPercentage of time wi thsensor glucose 
values between 70 and 180 mg/dL (both 
inclusive) , with CGM use during th e 
maintenance period
Secondary
To evaluate ICR with LY900014 treatment ICR at the end of the maintenance period 
To evaluate the relationship between ICR and 
TDD with LY900014 treatmentICR×TDD forthe maintenance peri od
To evaluate total daily, basal, and prandial 
insulin dose with LY900014 treatment and 
degludecPrandial: TDD rati o forthe maintenance 
period
Tertiary/Exploratory
To evaluate the safet y of LY900014 Adverse events and vital signs 
To explore the relationship between
ICR and TDD
ISF and TDD
ICR and ISF
with LY900014 treatmentSlope of the linear regressio n line of 
ICR or ISF on the reciprocal of TDD
Slope of the linear regressio n line of 
ICR on ISF, 
forthe maintenance peri od
To expl ore ISF wi th LY900014 treatment ISF at the end of the maintenance period
To explore glucose profiles, obtained fro m 
CGM use with LY900014 treatmentActual  and change from  baseline in mean 
sensor glucose with CGM use during the 
maintenance period
To explore highest PPG level wit hin 4 hours* 
after meal(s), obtained fro m CGM use, with 
LY900014 treatmentActual and change fro m baseline in highest 
PPG l evel within 4 hours after meal(s) ,with 
CGM use during the maintenance period 
CONFIDENTIAL I8B-MC-ITSZ (b)
27Objectives Endpoints
To explore the time fro m start of m eal to 
highest PPG level wit hin 4 hours* after 
meal(s), obtained fro m CGM use, with 
LY900014 treatmentActual  and change from  baseline in m inutes 
from start of m eal to hi ghest PPG l evel 
within 4 hours after meal(s) , with CGM use 
during the maintenance period 
To explore the percentage of tim e spent in 
hypoglycemic glucose ranges, obtained from 
CGM use, with LY900014 treatmentActual  and change from  baseline in 
percentage of time with sensor glucose 
values <54 mg/dL , withCGM use during 
the maintenance period 
To explore percentage of time spent in 
hyperglycemic glucose ranges, obtained fro m 
CGM use, with LY900014 treatmentActual  and change from  baseline in 
percentage of time with sensor glucose 
values >250 mg/dL , with CGM use during 
the maintenance period 
To explore within-day glucose variabilit y, 
obtained fro m CGM use, with LY900014 
treatm entActual  and change from  baseline in w ithin-
day CVof sensor gl ucose ,with CGM use 
during the maintenance period 
To explore proporti on of  participants achieving 
CGM -based glycem ic targets, with LY900014 
treatm entThe proporti on of  participants with 
percentage of time in 
target glucose range,
70-180 m g/dL, >70% 
hypoglycemia, <54 mg/d L, <1%
hyperglycemia, >250 mg/dL, <5% ,
with CGM use during the maintenance 
period 
To explore fructosamine with LY900014 
treatm entFructosamine at the end of the maintenance 
periodcompared to baseline
To explore HbA1c with LY900014 treatm ent HbA1c at the end of the maintenance period
compared to baseline
To explore 1,5 Anhydroglucito l(AG) with
LY900014 treatment1,5 AG at the end of the maintenance period
compared to baseline
Abbreviations: CGM = continuous glucose monitoring; CV = cardiovascular; HbA1c = hemoglobin A1c; ICR = 
insulin -to-carboh ydrate ratio ; ISF = insulin sensitivity factor ; PPG = post-prandial glucose ; TDD = Total Daily 
Dose .
* E xcluding the glucose data from pa rticipa nts who have had the next meal event before the end of time 
interval.
CONFIDENTIAL I8B-MC-ITSZ (b)
284. Study Design
4.1. Overall Design
Study  ITSZ is a m ulticenter, single- group , open -label, Phase 2 , expl oratory study  that will be 
conducted in participantswith T1D currently treated wi thinsulin degludec and a rapid -acting 
insulin analogin an MDI regimen. The obj ective of the study  is to assess the percentage of time 
glucose values are within the target range of70 to 180 mg/dL after 35 days o f titration using the 
study titration scheme.
The study  will consist of the followingperiods:
Screening and lead-inperiod
Treatment period
oTitration peri od
oMaintenance period
Safety follow-up peri od
4.1.1. Study Visits
Screening , Visit 1
The purpose of procedures at the screening visit is to establish eligibilit y for the study  (see
Secti ons 5.1and 5.2).Participants will continue their pre -study  rapid-acting insulin analog and 
their basal insulin dose .Insulin -to-carbohydrate ratio , insulin sensit ivity factor ( ISF),and DIA
shoul d not be changed unless for safet y reasons during the screening period. 
Lead -in Period , Visit 2
The l ead-in peri od starts following Visit 2.During the lead-in period, all participants will 
administer Hum alog as rapi d-acting insulin with the InPen Pen Injector. Participants who enter 
the study  on Novol og, Adm elog, or Api drawill transit ion to Hum alog at Visi t 2. The dose of 
insulin degludec and the ICR , ISF,and DIA should not be changed unless for safet y reasons.
Sponsor Provided CGM Sessio n
At Visit 2, Dexco m G6 CGM sensors andtransmit ter will be dispensed to all participants who 
meet study  entry  criteria. 
All p articipants will switch to a Lilly  provid ed Dexco m G6 CGM system during Visit 2. Also, 
any participant using a personal Dexco m G6 will switch to a Lilly provided Dexco m G6 during 
Visit 2. All  parti cipants will use Dexcom G6 CGM from Visit 2 until Visit 14 . Parti cipants will 
grant permissio n to the site to access their CGM data.
At Visit 2, participants will insert a new Lilly provided sensor and transmitter . Between Day -11
and Day 46, parti cipants will wear the study -provided G6 CGM system  and change the sensor 
every 10 days or as needed. All pa rticipants should use the sensor code printed on the back of the 
adhesive patch to calibrate when starting a new sensor. Calibrat ing Dexco m G6 CGM using 
fingerst ick meter value sis prohibited in this study to avoid increased sensor measurement
variabilit y across pa rticipants caused by  using different brands/models of glucose meters for 
calibrat ion. 
CONFIDENTIAL I8B-MC-ITSZ (b)
29All participants will use the Dexcom mo bile app on their smart phone to view their CGM data 
during the s tudy.Participants who enter the study using Dexco m G6 CGM willnot use their 
Dexco m G6 CGM receiver to view CGM data. 
Sites will work with the parti cipant to ensure :
theDexco m CGM m obile app is installed on the parti cipant’s smart phone 
participant hasan active Dexco mmobile app business account
CGM device and associated Mobile medical app (MMA )is set up so that
oall alerts and notifications are enabled
oalert levels are adj usted, if necessary
olocation services are enabled
participant grants permissio n to the site to vi ew hisor her CGM data through CLARITY
and SMS
During the l ead-in periodfrom Day -10 to Day  -1, participants are required to enter the fo llowing 
data into the Dexco mmobile app every  day: 
meal start time for breakfast, lunch, and dinner
insulin degludec dose
Invest igator staff should check CLARITY to ensure that participants are entering these data 
during the lead- in period. 
Training related to the use of Dexco m G6 CGM and its associated mobile app will be provided at 
Visit 2. Abbreviate d training following V isit 2 will be made available as deemed appropriate.
Minimum CGM Requirements
The CGM data collected during the lead -in period will be used as baseline CGM. Participants 
must have at least 5 day s with a minimum  of 70% CGM measures per day during the lead -in 
period to be eligible for treatment assignment. These 5 days do not need to be consecutive. 
The invest igator will have daily access to the SMS portal during the lead -in peri od and will print 
the participant’s Data Acceptabilit y Rep ort to determine the participant’s eligibilit y for treatm ent 
assignment. The investigator should determine before Visit 3 that the participant has met the 
minimum CGM eligibilit y requirements and then communicate to the participant their eligibilit y 
for treatm ent assi gnment. If the invest igator becomes aware through SMS portal mo nitoring 
during the lead- in period that a participant will not meet the minimum CGM requirements before 
Visit 3, the site shoul d advise the pa rticipant to re-schedule Visit 3 toa later date wi thin the visit 
window. 
InPen
During Visit 2, InPen Pen Injector and associated supplies will be dispensed to all participants 
who meet study  entry  criteria. The InPen mobile app will be downloaded onto the participants ’
smartphone. 
Sites will work wi th the parti cipant to ensure :
InPen m obile app i s installed on the participant’s smart phone
participant has an active InPen mobile app business account
CONFIDENTIAL I8B-MC-ITSZ (b)
30Parti cipants have entered the following information in the InPen device and associated 
MMA :
oTarget blood glucose: this is the blood glucose value the pa rticipant is trying to 
achieve. It is prescribed by invest igators and individualized for each pa rticipant in 
the study . The target blood glucose will be used by the dose calculator to calculate 
the correction bo lus and is dist inct fro m the glycemic targets used for insulin 
titration defined in Sect ion 4.3. 
oICR
oISF
oDIA
Parti cipants are requi red to enter meal or snack carbohydrates and current CGM glucose before 
each meal/snack into the InPen mobile app in order to use the bolus dose calculator during the 
study .
Training related to the use of InPen Reusable Pen Injector and its associated mobile app will be 
provi ded at Vi sit 2. Abbreviated training following Visit 2 will be made available as deemed 
appropriate.
Transcribing D ata into the eCRF at Vis it2
At Visit 2, the invest igator should transcribe the following data from the day before the visit into 
the eCRF:
ICR
ISF
DIA
Diabetes Educati on
Initial training related to di abetes education and nutrition counseling will be provided at Visit 2
and other visits as needed .Appropriate site personnel will administer education using locally 
approved diabetes education materials and programs or by  using other materials that may  be 
provi ded by the Sponsor.
Treatment Period , Visit 3 to Visit 14
Treat ment Assignment , Visit 3 (Day 0)
The invest igator should determine eligibilit y for treatm ent assignment before Visit 3. There will 
be no early enrollment if a participant meets the minimum 5 -day requirement of 70% CGM 
readings per day  before Visit 3. 
For participants who are eligible for treatm ent assignment , Humalog will be discont inued, and 
LY900014 will be init iated using their current ICR ,ISF, and DIA at Visit 3.All part icipants who 
are not currently administering insulin degludec in the morning shoul d swi tch to m orning 
administration with the invest igator’s guidance. All participants should cont inue administering 
degludec in the morning throughout the treatm ent peri od. 
CONFIDENTIAL I8B-MC-ITSZ (b)
31Titration Period , Visit 3 through Visit 13 (Day 0to Day 35)
Following treatm ent assi gnment at Visit 3, participants will enter a 35-day insulin t itration 
period. The invest igator may adjust the dose of insulin degludec, ICR, ISF, or DIA at any t ime 
from Visit 3 (Day  0) to Visit 13(Day  35)to meet the glucose targets specified in Section4.3.1 . 
Parti cipant’s ambulatory  glucose profile will be reviewed using CGM data from CLARITY at 
each visit . 
Parti cipant’s LY900014 dose wi ll be reviewed using the InPen report. The invest igator should 
confirm that the InPen report has been received before each study  visit. Addi tionally, the 
investigator should confirm that the InPen report aligns wit h the clinical management of the 
participant. Based on these reports, insulin doses, ICR, ISF , and DIA will be adjusted as needed 
to reach the study  specified gl ucose target (Section s4.3.1 and 4.3.2 ).
Maintenance Period, Day 36 to Day 46
The m aintenance peri od starts following Visit 13. Continuous gl ucose m onitoring data collected 
during the maintenance period will be used as endpoint CGM data. 
During the m aintenance period, the investigator may  not adj ust the dose of insulin degludec , 
ICR, ISF, or DIA unless for safet y reasons. 
During the m aintenance period from Day 36 to Day  45, participants are required every  day to 
enter the fo llowing data into the Dexco mmobile app
meal start time for breakfast, lunch, anddinner
insulin degludec dose
Invest igator staff should check CLARITY to ensure that participants are entering these data 
during the maintenance period. 
Visit 14 ( Day 46)
At Visit 14, participants will return to their non -study rapi d-acting insulin analog regimen. 
Parti cipants may  decide to con tinue to administer degludec in the morning or switch to their 
pre-study  dosing schedule. Theinvest igator will determine basal and prandial insulin doses. 
At Visit 14, participants will return to the personal CGM system  that they  were using bef ore the 
study  began. Parti cipants shoul d be reminded before Visit 14 that they will need to bring their 
personal CGM system  toVisit 14. 
Transcribing Data into the eCRF from Visit 3 to Visi t 14
At every  visit from Visit 3 to V isit 14inclusive , the invest igator should transcribe the fo llowing 
data from  the day  before the visit into the eCRF:
ICR
ISF
DIA
CONFIDENTIAL I8B-MC-ITSZ (b)
32Transcribing Data into the eCRF for Visit 3and Visit 14 only 
In addit ion to the ICR, ISF, and DIA, the investigator should transcribe the Hum alog dose at 
Visit 3 (data from  Day  -10 to Day -1) and the LY900014 dose at V isit 14 (data from Day 36 to 
Day 45).
Safety Follow-up, Visit 801
All rando mized participa nts who completed the treatment period shoul d have a safety  follow-up 
visit approximatel y 1 week after Visit 14.
Early Termination visit, ET Visit
Parti cipants who di scontinue investigational product ( IP)permanent ly before completion of the 
treatm ent peri od for any  reason will also be discontinued from the study . An (ET)visit shoul d be 
conducted as soon as reasonably possible . After the ET visit , a safety fo llow-up assessment 
(Visit 801) shoul d be conducted approximately  1 week after the ET Visit .
Transcribing Data into the eCRF at the ET Vi sit
At the early terminat ion visit, the investigator should transcribe the fo llowing data from the day 
before visit into the eCRF:
ICR
ISF
DIA
LY900014 dose
4.2. Scientific Rationale for Study Design
This study  will evaluate a new ti tration scheme of LY900014 in pa rticipants with T1D who use 
insulin degludec for basal glucose control in an MDI regimen. The study  will last up to 73 day s
and include an intensive insulin titration period of 35 day s followed by  a 11-day maintenance 
period. Thepercentage of time glucose values are within the target range of 70 to 180 mg/dL 
after 35 day s titration of using the study titration scheme will be evaluated. 
4.3. Justification for Dose
In clinical pract ice, prandial insulins are often titrated based on the ‘next pre -meal glucose’ . For 
example, clinicians use the pre-lunchblood glucose value to assess the adequacy  of the breakfast 
prandial dose. This commo nly used t itration scheme may not be optimized for the novel time -
action profile of LY900014. An alternate approach o f using peak PPG values or the change fro m 
pre-meal levels may be better -suited to titrating ultra -rapid act ing prandial insulins. In particular, 
the ‘faster on -faster off’ profile o f LY900014 might allow more aggressive prandial dosing that 
woul d further improve PPG without increasing the risk o f late post -meal hypoglycemia .
The basal and bo lus dosing of insulin in this study  will be individually  titrated based on real -time 
Dexco m G6 CGM readings andfrequent interaction with invest igator s. The Dexco m G6 CGM 
system has been approved by theFDA to repl ace fingerst ick blood glucose testing for diabetes 
treatm ent deci sions.
CONFIDENTIAL I8B-MC-ITSZ (b)
334.3.1. Target Glucose Values for Titration of Insulin Therapy
The overall glycemic control goals for all participants enro lled in the study  are generally similar 
to those recommended by the American Associat ion of Clinical Endocrino logists (AACE)
(Bailey et al. 2016). A target forovernight glucose excursio n (the difference between bedt ime 
and pre-breakfast glucose l evels )is also provided to guide insulin titration. 
Fasting glucose, overnight glucose excursio n, and post -prandial glucose target values used to 
reach the glucose goals and for determinat ionof titration in insulin therapy are listed as fo llows.
Time of Target Gluc ose Measurement Glucose Target (Range)
Fasting glucose 100 mg/dL (range 80 -110 mg/dL)
Overnight glucose excursion 
(the difference between bedtime and pre -breakfast 
glucose levels )≤±30 mg/dL
Postprandial glucose peak <140 mg/dL or <20% increase from premeal level
4.3.2. LY900014
Parti cipants will perform  carbohydrate counting for each meal and snack throughout the study . 
Participants should use the bo lus calculator funct ion on the InPen app to determine all 
meal /snack and correcti on doses. Prandial insulin dose is calculated based on the estimated 
carbohydrate con tent of the m eal and investi gator prescribed ICR. Parti cipants are allowed to eat 
snacks during the study . However, each snack should be covered by  bolus insu lin (if applicable) . 
Parti cipants shoul d routinely  use correcti on bol uses as needed for hy perglycemia management 
based on the invest igator -prescribed ISF. 
Treatment Period
During Visit 3, participants will receive instructions from the invest igator to dis continue their 
pre-study  rapid-acting insulin. LY900014 will be init iated unit -for-unit based on the pre -study 
ICR and ISF. LY900014 should be administered immediately (0 to 2 minutes) before the start of 
each m ealand snack (if applicable) .
During the ins ulin t itration peri od (Vi sit 3 to Vi sit 13), ICR ,ISF and DIA will be titrated by  
investigators based on Dexco m G6 CGM readings approximately  twice per week as needed (see 
Secti on 1.3SoA). E very e ffort shoul dbe made to reach the glycemic targets of :
Post-prandial glucose peak<140 mg/dL or
<20% ri se from pre- meal level
During the m aintenance period ( Visit13 to Visit 14), ICR ,ISF, and DIA will remain unchanged 
unless for safet y reasons. The insulin dose may be decreased at any  time throughout the 
treatm ent peri od for saf ety reasons. 
Safety follow-up peri od
At Visit 14, participants will switch back tothe pre -study  rapid-acting insulin. The dos e will be 
prescribed by  the invest igator. 
CONFIDENTIAL I8B-MC-ITSZ (b)
344.3.3. Insulin Degludec
Screening and lead -in peri od
During the screening and lead -in period, participants will cont inue the irpre-study  dose of insulin 
degludec and the dose shoul d be kept stabl e unl ess for safet y reasons such as hypoglycemia or 
unacceptable hyperglycemia . 
Treatment period
At Visit 3, participants who do not administer insulin degludec in the morning will fo llow the
investigator’s instructions to switch to morning dosing. All participants will administer insulin 
degludec in the morning fro m Visit 3 throughout the treatment period until the end of 
maintenance period, Visit 14.
During the insulin t itration peri od (Vi sit 3 to Vi sit 13), the insulin de gludec dose will be t itrated 
by the investigator based on Dexco m G6 CGM readings approximately  twice per wee kas needed
(see Section 1.3SoA) to rea chthe fasting glucose target of 100 m g/dL (range 80 to 110 mg/dL) .
Every effort shoul d be made to reach the overnight glucose excursio n target of ≤±30 mg/dL
during the titration period.
During the m aintenance period (Visit 13 to Visit 14), the dose of insulin degludec will be kept 
unchanged unless for safet y reasons. 
Safety follow-up peri od
During the safet y follow-up peri od (Visi t 14 to Vi sit 801), parti cipants m ay choose to continue to
dose insulin degludec in the morning or swi tch to a different dosing t iming . The dose of insulin 
degludec will  be prescribed by  the invest igator. 
4.4. End of Study Definition
The end o f the study  is defined as the date of the lastscheduled procedure for the last participant 
shown in the Schedule of Act ivities.
CONFIDENTIAL I8B-MC-ITSZ (b)
355. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is notpermitted. The study  popul ation will consist of 
participants with a diagnosis of T1D currently  being treated wi th insulin degludec and a rapi d-
acting insulin analog in an MDI regimen.
Eligibilit y of participantswill be based on the results of the assessm ents perform ed at screening
as described in the Schedule o f Activities (Sect ion 1.3). All screening evaluat ions must be 
completed and reviewed to confirm that potential participants meet all eligibilit y criteria.
The invest igator will maintain a screening log to record details o f all part icipants screened and to 
confirm eligibilit y or record reasons for screening failure , as applicable. The nature of any 
condi tions present at the time of the init ial screening and any preexist ing condit ions will be 
docum ented in the eCRF.
For screen failures and rescreening activit ies wi thin thescreening period, see Sect ion 5.4.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if allthe following cri teria apply:
Informed Consent
1.Capable of giving signed informed consent as described in Appendix 1 ,which includes 
compliance wi th the requi rements and restri ctions listed in the informed consent form 
(ICF) and in this protocol
Age and Se x
2.Parti cipant must be 18to 65years of age,inclusive, at the time of signing the informed 
consent.
3.Male or Female
Male: no contraception required
Female: A female participant is eligible to participate if she is not pregnant, intending 
to beco me pregnan t, or breastfeeding, and at least one of the following condit ions 
applies:
Is not a woman of childbearing potential (see Appendix 4, Secti on 10.4)
OR
Is a woman o f childbearing potential (WOCBP) and must agree to use one 
highly  effect ive method (less than 1% failure rate) of contraception, or a 
combinat ion of two effect ive methods of contraception for the ent irety of 
the study . Contraception requirements for participants are provided in 
Appendix 4(Secti on 10.4).
A WOCBP m ust test negative for pregnancy prior to init iation of 
treatm ent as indicated by  a negative serum pregnancy test at the screening 
CONFIDENTIAL I8B-MC-ITSZ (b)
36visit fo llowed by  a negat ive urine pregnancy text within 24 hours prior to 
exposure to invest igational product (IP) at Visit 3. 
Type of Participant and Disease Characteristics
4. H ave been clinically diagnosed wi th T1D for at least 1 year before screening, and 
continuously using intensive insulin therapy for at least 1 y ear. 
5.Have been on s table insulin requirements at the discretion of the investigator’s judgment 
with total daily  dose (TDD) ≤1.2 U/kg/d according to the average TDD fro m the three 
days before Visit 1
6.Have been on the same ty pe of rapid -acting insulin analog ( Hum alog U -100, Novolog , 
Admelog, or Apidra )for at least 30consecut ive days before screening 
7.Are proficient, in the opinion o f the invest igator, in carbohydrate counting and are willing 
to use carbohydrate counting to calculate bo lus doses throughout the study
8.Routinely use correction boluses as needed for hyperglycemia with stable correction 
factor in the opini on of the investi gator
9. Have been treated for at least 30 consecut ive days before screening with insulin degludec 
U-100 
10.Have an HbA1c value ≥6.0 and ≤8.0%, according to the central laboratory  at screening 
(Visit 1).
11.Have a body  mass index (BMI) of ≤35.0 k g/m2at screening (Visit 1).
12.CGM system
Must be using unblinded personal CGM for diabetes m anagement with total CGM 
use of 2months in the prior6 months
Mustbe willing and able to use a study-provi ded Dexco m G6 CGM system ,
including sensor and transmitter ,during the study and must cease use of their 
personal CGM system ,including Dexco m receiver if applicable
Mustbe willing and able to use the Dexco m mo bile applicat ion and grant si te 
permission to access their CGM data during the study
13.Must be willing to use InPen to inject rapid -acting insulin and share data with 
investigator via email 
14.Have access to Wi Fior a cellular data plan for transmissio n of data
15.Have an act ive email account 
16. H ave access to a Bluetooth enabled smart phone (either Andro id or iPhone) compatible 
with both the Dexco m and InPen mobile app lications for transmission o f the data
17.Have refrigerat ion in the ho me or have ready access to refrigeration for storage of insulin 
therapy
18.Have a regular sleep/wake cycle (for e xample, thosewho are awake during the day  and 
sleep during the night)
CONFIDENTIAL I8B-MC-ITSZ (b)
3719.Capable of andwilling to do the fo llowing:
a.Inject insulin wit h the use of an insulin injection device (insulin pen) 
according to manufacturer guidelines 
b.Follow the invest igator’s instructions to titrate insulin based on glucose 
targets
c.Able to read and understand the language(s) available for devices and applicat ions
used in the study
d.Com ply wi th the use of the study  insulin and scheduled visits
e.Receive diabetes education
5.2. Exclusi on Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
20.Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance 
due to neurologically  disabling hypoglycemia) within the last 90 day sbeforescreening
21. Have hypoglycemia unawareness as judged by the investigator
22.Have had more than 1 eme rgency room  visit or hospi talizati on due to poor gl ucose 
control  (hyperglycemia or diabetic ketoacidosis) wit hin 6 months beforescreening 
(Visit 1)
23.Have a scheduled surgery  or pl astic surgery during the study
24.Have cardio vascular disease wit hin the last 6 months before screening, defined as 
stroke 
decom pensated heart failure New York Heart Associat ion Class III or IV
myocardi al infarct ion
unstable angina pectoris 
coronary  arteri al bypass graft
25.Gastrointestinal
Have gastroparesis beforescreening
Underg one gastri c bypass or sleeve gastrectomy  (bari atric) surgery before
screening
Undergone restrictive bariatric surgery  (like Lap-Band®) before screening
26.Hepati c
Have acute or chronic hepat itis or cirrhosis
CONFIDENTIAL I8B-MC-ITSZ (b)
38Have obvious clinical signs or symptoms o f any other liver disease 
EXCEPT non -alcoho lic fatty liver di sease (NAFLD ). Those with NAFLD 
are eligible .
Have elevated liver enzyme measurements, as determined by the central 
laboratory  at screening according to the parameters are as fo llows:
i.Total  bilirubin ≥2times the upper limit of normal (ULN ; except 
for Gilbert’s syndro me)as defined by  the central  laboratory , or
ii.ALT/serum glutamic py ruvic transaminase (SGPT) ≥3times ULN
as defined by  the central  laboratory , or 
iii.Aspartate aminotransferase (AST)/serum glutamic oxaloacetic 
transaminase (SGOT) ≥3times ULN as defined by the central 
laboratory
27.Renal
History of renal  transplantati on
Current ly receiving renal dialysis
Serum  creatinine >2.0 mg/dL (177 µmo l/L) at screening as measured by  
the central  laboratory
28.Cancer
Have act ive or untreated malignancy 
Have been in remissio n from clinically  significant malignan cy (other than 
basal cell or squamous cell skin cancer) for less than 5 y ears
At increased risk for developing cancer or a recurrence of cancer in the 
opinio n of the invest igator
29.Have any other serious disease or condit ion (for example, known drug or alco hol abuse 
or psy chiatri c disorder) that, in the opinio n of the investigator, would pose a significant 
risk to the pa rticipant, precl ude the pa rticipant from following and com pleting the 
protocol , or interfere with the interpretation of safety , efficacy , orPD data
30.Have visio n or hearing loss that impairs recognit ion of CGM screens, alerts and alarms
31.Have experienced significant weight loss or gain (>5%) in body  weight in the 3 m onths 
before screening
32.Have known hypersensit ivity or allergy  to any  of the stud y medicat ions or their 
excipients
33.Have had a blood transfusio n or severe blood loss within 3 mo nths beforescreening or 
have any hematologic condit ion that m ay interfere with HbA1c measurement ( for 
example , hem oglobinopathy, hemo lytic anemia, and sickle-cell disease)
Prior/Concomitant Therapy
CONFIDENTIAL I8B-MC-ITSZ (b)
3934.Are taking drugs that may significantly affect glycemic control ( for example , niacin 
[allowed if <1.0 g/day ], bile acid sequestrants)
35.Glucocorti coid therapy
Arecurrent lyreceiving chronic (l asting longer than 7 consecut ive days) 
systemic glucocorti coid therapy  through the fo llowing preparati ons
i.Intravenous
ii.IM
iii.Subcutaneous
iv.Oral
v.Intra -articular
Have received such therapy  within 4weeks immediately before screening 
except forreplacement therapy  for adrenal  insufficiency
36.Are current ly taking ,or have taken within the 3 months preceding screening, prescript ion 
or over -the-coun ter m edicat ions to promote weight loss
37.Are using any oral ,injectable , or inhaled (except for the occasional, supplemental  use of
Afrezza) medication intended for the treatment of diabetes mellitus other than an MDI 
regimen including a rapid-acting insulin analog and a basal insulin analog in the 90 days 
before screening
Prior/Concurrent Clinical Study Experience
38. Are current ly enrolled in any other clinical study  involving an IP or any other type of 
medical research judged not to be scient ifically or medically co mpat ible with this study
39. H ave part icipated, within the las t 30 days in a clinical  trial invo lving an IP. If the 
previous IPhas a long ha lf-life, 3 months or 5 half -lives (whichever is lo nger) should 
have passed
Other Exclusions
40.Per the principal invest igator’s discret ion, is not techno logically com petent
41. Are unable and/or unwilling to provide inf ormed consent, to m ake themselves available 
for the durati on of  the study , to com ply with the use of a data collection device to direct ly 
record data, or to abide by  study  procedures
42.Are invest igator site personnel directly affiliated wit h this study  and/o r thei r immediate 
families. Immediate family  is defined as a spouse, parent, child, or sibling, whether 
biological  or legally  adopted
43.Are Lilly  empl oyees or representatives (including emplo yees, tem porary  contract 
workers, or designees responsible for the conduct of the study )
5.3. Lifestyle Considerations
During the study , participan ts must avo id:
CONFIDENTIAL I8B-MC-ITSZ (b)
40donating blood or blood products
major changes in diet or exercise
5.3.1. Meals and Dietary Restrictions
During the study , participants should avo id majo r changes in diet or exercise . Parti cipant s should 
have 3 doses of prandial insulin per day  and eat 3 main meals per day  (morning, mi dday , and 
evening) on a regular basis. Snacking is allowed ifit is covered by  a bol us dose of rapi d-acting 
insulin (ifapplicable) .
5.3.2. Activity
During the study , parti cipants shoul d cont inue their usual exercise habit andavoid majo r changes 
in exercise. Participan tsshoul d not receive an intensive exercise program with the intent of 
reducing body  weight at any  time during the study .
5.4. Screen Failures
Individuals who do not m eet the cri teria for parti cipati on in this study  (screen failure) m ay not be
rescreened. Individuals who were required to unexpectedly discont inue from the study  during 
screening or the lead-in period ( for example, due to enrollment pause related to the COVID -19 
public healt h emergency) will be allo wed one rescreening. All pa rticipants that rescreen will 
restart at Visit 1 and co mplete all screening procedures.
Retesting of laboratory  samples is not allowed, except for cases in which results are not available 
from the original  sample.
CONFIDENTIAL I8B-MC-ITSZ (b)
416. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to a study  parti cipant according to the 
study  protocol .
6.1. Study Intervention(s) Administered
Interven tion Name LY900014 Degludec
Type Drug Drug
Dose Formulation Solution Solution
Unit Dose Strength(s) 100 units/mL 100 units/mL
Dosage Level(s) Individualized dosing Individualized dosing
Route of Administration Subcutaneous Subcutaneous
Use Experimental prandial insulin
(0-2 minutes before start of meal or 
snack [if applicable] )Basal insulin
IMP and NIMP IMP NIMP
Sourcing Provided centrally by the Sponsor Provided centrally by the Sponsor
Abbreviations: IMP = Investigational Medicinal Product ; NIMP = Non -Investigational Medicinal Product
6.1.1. Medical Devices
The medical device for use in thi s study  is the InPen .
Manufacturer i nstructi ons f or use for InPen are available at www.companio nmedical.co m.
All device deficiencies (including malfunct ion, use error and inadequate labeling) shall be 
docum ented and reported by  the i nvest igator throughout the clinical invest igation (see 
Secti on8.3.7 ) and appropriately managed by the sponsor.
CONFIDENTIAL I8B-MC-ITSZ (b)
426.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have 
been maintained during transit for all study  intervent ion received and any 
discrepancies are reported and resolved before use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion and only 
authori zed si te staff may  supply  or administer study  intervent ion. All study  
intervent ion must be stored in a secure, environmentally controlled, and mo nitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h 
access limited to the invest igator and authorized sit e staff.
The invest igator, insti tution, or the head of the medical inst itution (where applicable) 
is responsible for study  intervent ion accountabilit y, reconciliat ion, and record 
maintenance ( that is, recei pt, reconciliat ion, and final disposit ion records).
All insulin products must be s tored at the invest igative site under refrigerated 
condi tions ( between 2°C and 8°C) in a locked and secure place. Insulin must not be 
frozen.
In-use insulin shoul d be maintained at room temperature. In -use insulin must not be 
used after 28 day s.
6.3. Measures to Minimize Bias: Randomization and Blinding
This is a single -group , open -label study . 
6.4. Study Intervention Compliance
Com pliance for CGM will be assessed by the Clarity  report sand SMS reports during all site 
visits. Com pliance for prandial insulin administration will be assessed by the InPen report during 
all site visi ts. If the invest igator deems that the participant is noncompliant with CGM or prandial 
insulin administration, the participant may be discontinued fro m the study .
Concomitant m edicat ion compliance and adherence to the visit window will be assessed by  
direct questi oning during all site visi ts. If a participant is deemed noncompliant, he or she will 
receive addit ional diabetes educat ion and training and the importance of compliance wi th the 
protocol  will be reinforced. If the participant continues to be noncompliant in the opinio n of the 
investigator, then the participant will be discont inued fro m the study .
A record of the number of LY900014 cartridges dispensed to and t aken by each participant must 
be maintained and reconciled wit h study  intervention and compliance records. Intervent ion start 
and stop dates, including dates for intervent ion delays and/or dose reductions will also be 
recorded in the CRF.
6.5. Concomitant Thera py
The fo llowing concomitant therapies 
Are NOT allowed at any  time during the study :
oAcetaminophen dosed in quantit ies greater than 1 gram every  6 hours
CONFIDENTIAL I8B-MC-ITSZ (b)
43oNon-study  insulin (except for device failure when pa rticipants can switch to pre-exist ing 
rapid-acting insulin for a maximum o f 48 hours)
oNon-insulin injectables for the treatment of diabetes ( for example, pramlint ide, glucagon -
like peptide -1 [GLP -1]agonists)
oOral antidiabetic m edicat ions: dipept idyl pept idase -4inhibitors, Sodium -glucose 
co-transporter -2inhibitors , GLP -1 agonists, metformin, sulfonylureas, glinides, 
alpha-glucosi dase inhibitors, and so on
oSystemic glucocorti costeroi ds
oIntra -articular steroid preparations
ARE allo wed at any  time during the study
oInhaled, intranasa l intraocular, and non -occlusive, limited topical steroi d preparati ons
Lilly Medical shoul d be contacted if there are any  questi ons regarding concomitant or prior 
therapy .
6.6. Dose Modification
Dosing will be individualized based on readings from the study -provi ded Dexcom G6 CGM and 
through frequent interactions wit h investigators . See Section 4.3for details o f dose m odificat ion.
6.7. Intervention after the End of the Study
LY900014 will not be made available to pa rticipants after conclusion o f the study .During the 
safet y follow-up peri od, pa rticipants will return to the rapid -acting analog insulin regimen they 
had before the treatment period. Participants m ay choose to conti nue to dose insulin degludec in 
the morning or swi tch to an evening dose. The investigator will determine the dose for the rapi d-
acting analog insulin and for degludec.
CONFIDENTIAL I8B-MC-ITSZ (b)
447. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
7.1. Discontinuation of Study Intervention
Parti cipants who need to permanent ly discont inue from study  treatm ent will  also be discont inued 
from the study. At the time o f discontinuing fro m the study , if possible, an early  discontinuat ion 
visit should be conducted. After the early discont inuation visit, a safet y follow-up assessment 
(Visit 801) shoul d be conducted approximately  1 week after the early  terminati on visi t.
Please s ee the SoA for the timing o f these visits, for data to be collected at the time of study  
discontinuat ion and fo llow-up ,and for any  further evaluat ions that need to be completed .
Discontinuati on is expected to be uncommo n.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant will be wit hdrawn from the study  in the fo llowing ci rcumstances:
if he or she uses a non-study rapi d-acting insulin for a period greater than 48 hours during 
the treatment period . 
if he or she loses contact with the site for more than 10 days. 
if he or she uses prohibited conco mitant m edicati on during the study as specified in 
Secti on6.5.
A participant may withdraw from  the study :
at any  time at his or her own request 
at the request of his or her designee (for example, parents ,or legal guardian)
at the discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons
if the participant beco mes pregnant during the study
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
if the participant , for any  reason, requi res treatm ent wi th another therapeuti c agent that 
has been demonstrated to be effect ive for treatment of the study indicat ion, 
discontinuat ion from the study  occurs before introduction of the new agent
if the invest igator, after consultation with the sponsor -designated medical mo nitor, 
determines that a systemic hypersensit ivity react ion has occurr ed related to study drug 
administration, the participant should be permanently discont inued from the 
investigat ional drug. 
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  retain 
and cont inue to use any data colle cted before such a withdrawal o f consent. If a participant 
withdraws fro m thestudy , heor she may request destruction of any  samples taken and not tested, 
and the invest igator must document this in the site study records.
CONFIDENTIAL I8B-MC-ITSZ (b)
457.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  treatm ent unl ess 
there are extenuating circumstances that make it medically necessary for the participant to 
continue on study  treatm ent. If the investigator and the sponsor clinical research physician (CRP )
agree that it is medically appropriate to con tinue, the invest igator must obtain documented 
approval  from the sponsor CRP to allow the inadvertently  enrolled parti cipant to continue in the 
study  with or wi thout treatm ent wi th invest igational product.
Safety follow-up isas outlined in Sect ion 1.3(Schedule of Act ivities), Secti on 8.2(Safet y 
Assessments) , and Secti on8.3(Adverse Events and Serious Adverse Events) of the protocol.
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she loses contact with the study  site for 
more than 10 days.Site personnel are expected to make diligent attem pts to contact parti cipants 
who fail to return for a scheduled visit or were otherwise unable to be fo llowed up by  the si te.
CONFIDENTIAL I8B-MC-ITSZ (b)
468. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA. Protocol waiver s or 
exempt ions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al 
participant s meet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all partici pants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
8.1. Efficacy Assessments
8.1.1. Primary Efficacy Assessments
The primary  efficacy  measure is the change fro m baseline in percentage of time wi th sensor 
glucose values between 70 and180 m g/dL (both incl usive), from CGM use in the maintenance 
period.
8.1.2. Secondary Efficacy Assessments
Secondary  efficacy assessments for this study  are
Change from baseline in ICR at the end of the maintenance period
ICR×TDD forthe maintenance peri od
Prandial :TDD rati o forthe maintenance peri od
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA Secti on 1.3.
Theactual  and change fro m baseline in percentage of time wit h sensor glucose values 
<54mg/dL will be evaluated withCGM as an exploratory  object ive.
8.2.1. Physical Examinations
A co mplete physical examinat ion will include, at a minimum, assessments of the cardiovascular, 
respiratory , gastrointestinal ,and neurol ogicalsystems. Height and weight will also be measured 
and recorded.
Invest igators should pay special attenti on to clin ical signs related to previous serious illnesses.
8.2.2. Vital Signs
For each participant , vital signs m easurements shoul d be conducted according to the Schedule of 
Activities (Section 1.3).
CONFIDENTIAL I8B-MC-ITSZ (b)
478.2.3. Electrocardiograms
Single 12-lead ECG will be obtained as outlined in the SoA (see Section 1.3) using an ECG 
machine that automat ically calculates the heart rate and measures PR, QRS, and QT.
8.2.4. Clinical Safety Laboratory Assessments
See Secti on 10.2 (Appendix 2 )for the list of clinical laboratory  tests to be performed and to the 
SoA for the timing and frequency. See Secti on 10.5 (Appendix 5) for clinical laboratory  testing 
for close hepat ic monitoring and see Secti on 10.2.1 for clinical laboratory testing for 
hypersensit ivity.
The invest igator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study  in the AE section of the CRF. The 
laboratory  reports m ust be f iled wit h the source documents. Clinically significant abnormal 
laboratory  findings are those which are not associated with the underlying disease, unless judged 
by the investigator to be more severe than expected for the participants ’condi tion.
All labor atory  tests wi th values considered clinically significantly abnormal during participat ion 
in the study  shoul d be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by  the investi gator or m edical mo nitor.
If such values do not return to normal or baseline within a period of time judged reasonable by 
the invest igator, the etio logy shoul d be i dentified and thesponsor notified.
All protocol -requi red laboratory  assessments, as defined in Section 10.2 (Appendix 2 )and the 
assessments described in Secti on 10.5 (Appendix 5) and Secti on 10.2.1 , must be conducted in 
accordance with the laboratory  manual and the SoA.
If laboratory  values fro m non-protocol -specified laboratory  assessments perform ed at the 
institution’s l ocal laboratory requi re a change in parti cipant m anagement or are considered 
clinically significant by  the investi gator ( for example , SAE or AE or dose modificat ion), then the 
resul ts must be recorded in the CRF.
8.2.5. Self-monitoring of Blood Glucose
Self-monitoring o f blood glucose is optional in this study . Insulin t itration will be guided by real -
time CGM readings fro m the Dexco m G6 CGM during thi s study . Dexcom  G6 CGM has been 
approved by  FDA f or making clinical decisi ons. In case gl ucose al erts and readings from  
Dexco m G6CGM do not m atch pa rticipant’s symptom s, the pa rticipant can use a finger st ick 
blood glucose value to make treatment decisio ns.
All pa rticipants will wear Dexco m G6 CGM throughout the study  until  the end of m aintenance 
period. Calibrat ing Dexcom G6 CGM using finger sti ck m easurement is not allowed. All 
participants should use the sensor code printed on the back of adhesive patch to calibrate when 
starting a new sensor.
8.2.6. Hypoglycemia
Participants will be trained about signs and symptoms of hypoglycemia, ho w to treat 
hypoglycemia, and how to discuss hypoglycemic events with invest igators.
CONFIDENTIAL I8B-MC-ITSZ (b)
48Hypoglycemia will be described using the following definit ions:
Level 1: Glucose <70 mg/dL (3.9 mmo l/L) and ≥54 m g/dL (3.0 mm ol/L)
Level 2: Glucose <54 mg/dL (3.0 mmo l/L)
Level 3: Severe hypoglycemia:
A severe event characterized by altered mental and/or phy sical status requi ring 
assistance for treatment of hypoglycemia. Participant s have altered mental status and 
cannot assist in their own care, may be semiconscious or unconscious, or experience 
coma with or wi thout sei zures, and requi re assistance of another person to actively  
administer carbohydrate, glucagon, or other resuscitat ive act ions. Glucose
measurements may  not be available during such an event, but neurological recovery  
attributable to the restoration of blood glucose concentration to normal is considered 
sufficient evidence that the event was induced by a low blood glucose concentrati on. 
The determinat ion of a hypoglycemic event as an episode of severe 
hypoglycemia, as defined above, is made by  the investi gator based on the 
medical need of the participant to have required assistance and is not 
predi cated on the report of a participant simp ly having received assistance.
All episodes of severe hypoglycemia must be reported as SAEs on the AE 
eCRF page and on the SAE eCRF page. 
Any events of severe hypoglycemia categorized as level 3 per the evaluat ion of invest igators will 
be co llected fro m ICF signing to Visit 801. 
Episodes of hypoglycemia categori zedas level 1 or level 2 will be analyzed based on data from 
the CGM sensor sessio n. Therefore, level 1 and level 2 hypoglycemic events do not need to be 
reported as an AE.
8.2.7. Safety Monitoring
The p rinciple invest igator will monitor safet y and laboratory  data throughout the study and 
shoul d discuss s afety concerns wit h the sponsor immediately upon occurrence or awareness of 
the concern to determine whether the participant should continue or discontin ue study  drug .
8.2.7.1. Hypersensitivity Reactions
Many  drugs, but parti cularly bio logic agents, carry therisk of systemic hypersensit ivity 
reacti ons. If such a reaction occurs, the event will be reported as a spontaneous AE. Addi tional 
data describing each sympto m shoul d be provi ded to the sponsor in the eCRF .
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving study  drug. It is recommended that participants 
who experience a system ic hypersensit ivity react ion be treated per the local standard of care.
In the case of generalized urticaria or anaphylaxis, additional blood,orurine samples shoul d be 
collected as described in Secti on 10.2.1 . Laboratory resul tsare provi ded to the sponsor via the 
central  laboratory .
CONFIDENTIAL I8B-MC-ITSZ (b)
498.2.7.2. Hepatic Monitoring
If a participant develops symptoms that warrant liver funct ion assessment ,liver function tests as 
detailed in Section 10.5 shoul d be perform ed.If thesetests are abnormal, clinical and laboratory 
monitoring shoul d be ini tiated by  the invest igator. 
8.3. Adverse Events and Serious Adverse Events
Adverse eventswill be reported by  the parti cipant ,or when appropriate, by  a caregiv eror
surrogate ..
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  intervent ionor the study  (See Secti on 7).
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All AEs occurring after signing the ICF are recorded in the AE eCRF and assessed for serious 
criteria.
The SAE reporti ng to s ponsor begins after the participant has signed the ICF and has received 
study  drug. However, if an SAE occurs after signing the ICF, but before recei ving LY900014, i t 
needs to be reported ONLY if it is considered reasonably possibly related to study  procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Secti on 10.3 (Appendix 3 ). The 
investigator will submit any updated SAE data to the sponsor within 24 hours of i t being 
available.
Invest igators are not obligated to actively seek AE or SAE after conclusi on of the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any  time after 
a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAEreports are provided in Section10.3 (Appendix 3).
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences .
8.3.3. Follow -up of AEs and SAEs
After the init ial AE or SAE report, the invest igator is required to proactively fo llow each 
participant at subsequent visits or contacts. All SAEs, and AEs of special inter est (as defined in 
Secti on 8.3.6 ), will be followed unt il resol ution, stabilizat ion, the event is otherwise explained, 
or the participant is lost to follow-up (as defined in Secti on7.3). Further informat ion on fo llow-
up procedures is provi dedin Section 10.3 (Appendix 3).
CONFIDENTIAL I8B-MC-ITSZ (b)
508.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator tothe sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the local regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regul atory requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB)/Independent Ethics Co mmittees 
(IEC), and invest igators.
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informat ion (for example , summary or list ing of SAEs) fro m the sponsor will review and 
then file it along with the IBand will notify the IRB/IEC, if appropriate according to local 
requi rements.
8.3.5. Pregnancy
Pregnancy (maternal or paternal exposure to study treatm ent) does not meet the d efinit ion of an 
AE. However, to fulfill regulatory  requi rements, any  pregnancy  should be reported following the 
SAE process described in Section 10.4 (Appendix 4) to collect data on the outcome for both 
mother and fetus.
Details o f all pregnancies in female participants and, if indicated, female partners of male 
participants will be co llected after the start of study intervent ion and unt il a period that i s at l east 
5 terminal half -lives after the last dose.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Section10.4 (Appendix 4).
Abnorm al pregnancy outcom es (for example , spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
8.3.6. Adverse Events of Special Interest 
There are no adverse events of special interest (AESIs) in Study  ITSZ. 
8.3.7. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the identit y, quality, durabilit y, reliabilit y, safety, effect iveness ,or performance of 
product s provided in the study.
Sponsor collects product complaints on investigational products and drug delivery systems used 
in clinical studies in order to ensure the safet y of study parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Parti cipants will be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
Product complaints will be reported by  the invest igatorto the sponsor per the Product Complaint 
Form .
CONFIDENTIAL I8B-MC-ITSZ (b)
51Note: Adverse events or SAE sthat are associ ated wi th a product complaint will also follow the 
processes outlined in Sect ion 8.3.3 andSection 10.3 (Appendix 3) of the protocol .
8.3.7.1. Time Period for Detecting Product Complaints
Product complaints that resul t in an AE will be detected, documented, and reported to the 
sponsor during all periods of the study  in which the drug or device is used.
If the invest igator learns of any product complaint at any time after a participant has been 
discharged from  the study , and such incident is considered reasonably related to a drug or device
provi ded for the study , the invest igator will pro mptly notify  the sponsor.
8.3.7.2. Prompt Reporting of Product Complaints to Sponsor
The Product Complaint Form will be available to the i nvest igator on an invest igator site portal
andall product com plaints will be reported according to the instructions on the form . 
Addit ionally , the invest igator will be supplied wit h product complaint reporting training 
materi als. 
8.3.7.3. Follow -up of Product Com plaints
Follow-up applies to all participants, including those who discont inue study  intervent ion.The 
investigator is responsible for ensuring that fo llow-up includes any supplemental invest igations 
as indicated to elucidate the nature and/or causalit y ofthe product com plaint. New or updated 
inform ation will be recorded on the originally co mpleted form with all changes signed and dated 
by the investigator and submitted to the sponsor.
8.4. Treatment of Overdose
In the event of an overdose, refer to the IB for LY900014, or to the product label for degludec.
Decisio ns regarding dose interruptions or modifications will be made by the invest igator in 
consultation wit hthe Medical Moni torbased on the clinical evaluat ion of the participant.
8.5. Pharmacokinetics
Not app licable.
8.6. Pharmacodynamics
Not applicable. 
8.7. Genetics
Not applicable
8.8. Biomarkers
Not applicable.
8.9. Immunogenicity Assessments
Notapplicable .
CONFIDENTIAL I8B-MC-ITSZ (b)
528.10. Health Economic s
Not applicable.
CONFIDENTIAL I8B-MC-ITSZ (b)
539. Statistical Considerations
9.1. Statistical Hypotheses
As an exploratory  pilot dose optimizat ionstudy , the primary objective of Study ITSZ is to
evaluate the percentage of time with glucose values wi thin target range (70 to 180 mg/dL , both 
inclusive )after 35 days of using the study titration scheme with LY900014 treatm ent and 
degludec.
The study  will invest igate if a more aggressive ICR is needed wit h LY900014 treatment for
participantsto reach the study -specific glucose target , compared to t he “500 Rule ” that is 
currently used in clinical pract ice.
9.2. Sample Size Determination
Approximately 34participants willbe assigned to study treatm entsuch that 30evaluable 
participants willcomplete the maintenance period, assuming a 10% dropout rate .
The study is not strict ly powered to demonstrate a statist ically significant change fro m baseline
in the primary endpo int(percentage of time with glucose wi thin 70 to 180 m g/dL) because o f the
exploratory  nature of the study . 
Using a standard deviat ion of 12%, t he sample will provi de approximately 80%coverage 
probabi lity that the half -width of the 95% confidence interval o f thechange fro m baseline in the 
primary  endpoint falls wit hin4.93%.
9.3. Populations for Analyses
The following popul ations are defined:
Population Description
Entered All pa rticipants who give informed consent
Enrolled All participants who continue the study after Visit 2
Treated All assigned pa rticipants who receive at least 1 dose of the assigned study treatment after 
Visit 3
9.4. Statistical Analyses
Statistical analysis o f this study will be the responsibilit y of Lilly or i ts desi gnee. Any  change to
the data analysis methods described in the protocol will require an amendment ONLY if it
changes a principal feature of the protocol. Any other change to the data analysis methods
describe d in the protocol, and the just ificat ion for making the change, will be described in the
statist ical analysis plan (SAP) or the clinical study  report. Addit ional exploratory analyses of 
data will be conducted, as deemed appropriate.
9.4.1. General Considerations
Unless otherwise specified, all efficacy and safet yanalyses will be conducted on the Treated 
Popul ation. Unless otherwise noted, all tests will be conducted at a 2 -sided alpha level o f 0.05 , 
and confidence intervals will be calculated at 9 5%, 2-sided.Com parison between baseline and 
CONFIDENTIAL I8B-MC-ITSZ (b)
54endpo ints will be performed at the full significance level o f 0.05. No mult iplicit y adjustment will 
be made. Baseline is defined as the last non -missing measurement at or before the treatm ent 
assignment (Visit 3) unless otherwise specified.
An analysis o f covari ance (ANCOVA) will be used to analyze continuous variables that are 
planned to be collected only  for baseline and endpoint. The model will include baseline as a 
covari ate.
A restricted -maximum -likelihood -based, mixed model repeated measures (MMRM) analysis will 
be used to analyze continuous longitudinal variables collected only  at baseline and more than one 
scheduled post-baseline visits according to SoA in Section 1.3. All the lo ngitudinal observat ions 
at each scheduled post -baseline visit will be included in the analysis. The m odel for the analysis 
of the primary  efficacy endpoint will include the fixed class effect of visit, and the rando m effect 
of patient. An unstructured covariance structure will be used to model the within -patient errors. 
Significance tests will be bas ed on least -squares (LS) means and Type III tests. SAS PROC 
MIXED will be used to perform the analysis. If this analysis fails to converge, the following 
covari ance structures will be tested in order:
Toeplitz with heterogeneit y
Autoregressive with heterogeneit y
Com pound symmetry  with heterogeneous variances
Toeplitz
Autoregressive
Com pound symmetry  without heterogeneous variances
The first covariance structure thatconverges will be used. The Kenward -Roger approximat ion 
will be used to estimate deno minator degrees of freedom. If the analysis still does not converge 
with Compound symmetry  without heterogeneous variances, only  summary stati stics will be 
provi ded.
For continuous measures, summary statist ics will include sample size, mean, standard deviat ion, 
median, minimum, and maximum for both the actual and the change fro m baseline 
measurements. Least -square (LS) means and standard errors derived fro m the analysis models 
will also be displayed for the actual  and the change fro m baseline measurements.
For categorical measures, summary  statisticswill include sample size, frequency, and 
percentages. No stati stical analyses will be conducted for baseline and endpoint comparison.
All CGM outcom e vari ables will only  be derived for Visit 3 (baseline) and Visit 14 (endpo int)
based upon the CGM data collected fro m valid CGM days , excluding data (if any) that are 
collected while patients aretemporarily off Humalog during the lead -in peri od or tem porarily  off 
IP duri ng the maintenance period. A valid CGM day  tobe counted into the calculat ion for a vi sit
must have at least 70% of the total  measures that are supposed to be obtained .
9.4.2. Primary Endpoint(s )
The primary  object ive of this study  is to evaluate the percentage of time with glucose values 
within target range (70 to 180mg/dL , both inclusive )after 35 days of using the study titration 
CONFIDENTIAL I8B-MC-ITSZ (b)
55scheme with LY900014 treatment and deglude c.Both actual  and change fro m baseline will be 
derived and analyze dby the ANCOVA modelas described in Section 9.4.1 .
The primary  analyses will  be conducted based upon the CGM data collected for Visit 3 
(baseline) and Visit 1 4(endpoint) , excluding data (if any) that are collected while pat ientsare
temporarily off Humal og during the l ead-in period or temporarily off IP during the maintenance 
period.
9.4.3. Secondary Endpoint(s)
Addit ional continuous secondary  efficacy variables, as well as the change from baseline for these 
variables, will be analyzed by the MMRM or ANCOVA model as described in Section9.4.1 .
Relationships between ICR and TDD will be evaluated through regression lines (ICR versus 
1/TDD) and compared with the “500 Rule ,”which is current ly used in clinical pract ice where 
ICR = 500/ TDD (Section 2.1).
9.4.4. Exploratory Endpoints
Addit ional continuous exploratory  efficacy variables, as well as the change from baseline for
these variables, will be analyzed by the MMRM or ANCOVA model described in Sect ion9.4.1 , 
unless otherwise specified.
Relationships between the following endpo ints will be explored through regression lines ( King et 
al. 2007 a, 2007b ).
ISF and 1/TDD
ICR and ISF 
TBD and weight 
9.4.5. Other Safety Analyse s
Safety measures will include AEs, vital signs, andtreatm ent exposure. Events that are newly 
reported after the first dose of IP used or reported to worsen in severit y from baseline (details 
will be described in SAP) will be considered TEAEs. 
Analyses of AEs will be descript ive and include alldata collected during the treatment period . 
AEs during the lead-in period and thesafet y follow-up period will be provided in a list ing.
Serious AEs, AEs reported as the reason for discontinuat ion from the IP or study, and TEAEs 
will be summarized in tabl es using the Medical Dictionary  for Regulatory  Activities (MedDRA) 
Preferred Term sorted by  decreasing frequency . Treatm ent-emergent AEs will also be 
summarized by  preferred term  sorted by  decreasing frequency wit hin the SOC for all TEAEs and 
by maximum se verity. For events that are gender -specific (as defined by MedDRA), the 
deno minator and computation of the percentage will include only pat ients from the given gender. 
The number and proportion of pat ients with at least 1 event for each ty pe of  event will also be
summarized.
In addit ion, time in hypoglycemic ranges will be assessed by  CGM analyses . 
9.4.6. Other Analyses 
Analysis details for addit ionalexploratory endpo ints will be described in the SAP.
CONFIDENTIAL I8B-MC-ITSZ (b)
569.5. Interim Analyses 
No interim analyses are planned for this study . If an unplanned interim analysis is deemed
necessary , the appropri ate Lilly medical director, or designee, will be consulted to determine 
whether it is necessary to amend the protocol.
9.6. Data Monitoring Committee
No Data Monitoring Co mmittee is planned f or thi s study . 
CONFIDENTIAL I8B-MC-ITSZ (b)
5710. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit hthe protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable Internat ional Council for Harmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents 
(for example , advert isements) must be submitted to an IRB/IEC by  the invest igator and reviewed 
and approved by the IRB/IEC before the study  is initiated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for change s necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or 
more frequent ly in accordance wit h the requirement s, policies, and procedures 
established by  the IRB/IEC
Notifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures
Provi ding oversight of the conduct of the study at the site and adherence to 
requi rements of 21 Code of Federal Regulat ions (CFR), ICH gui delines, the IRB/IEC, 
European regulat ion 536/2014 for clinical studies (if applicable), and all other 
applicable local regulat ions
Invest igator sites are compensated for participat ion in the study  as detailed in the c linical trial 
agreem ent
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosur e statem ents to the appropri ate regul atory  authori ties. Investi gators are 
responsible for providing informat ion on financial interests during the study  and f or 1 year after 
completion of the study .
CONFIDENTIAL I8B-MC-ITSZ (b)
5810.1.3. Informed Consent Process
The invest igator or his or her representative will explain the nature of the study , incl uding the 
risks and benefits, to the parti cipant and answer all questions regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants will be required to 
sign a statem ent of  inform ed consent that meets the requirements of 21 CFR 50, l ocal 
regul ations, ICH guidelines, Health Insurance Portabilit y and Accountabilit y Act (HIPAA) 
requi rements, where applicable, and the I RB/IEC or study  cente r.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. The 
authori zed person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant and is kept on file .
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be inform ed that hi sor her personal study -related data will be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of disclosure m ust also b e 
explained to the participant who will be required to give consent f or thei r data to be used as 
described in the informed consent .
The parti cipant must be inform ed that hi sor her medical records may be examined by Clinical 
Qualit y Assurance auditorsor other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
10.1.5. Dissemination of Clinical Study Data
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly  available website where required by local law or regulat ion. 
Data 
The sponsor provides access to all individual part icipant data collected during the t rial, after 
anonymizat ion, wi th the excepti on of  PK or genetic data. Data are available to request 6 months 
after the indicat ion studied has been approved in the United States (US) and European Unio n 
(EU) and afterthe primary  publicati on acceptance, which ever is l ater. No expirat ion date of data 
requests is current ly set once data are made available. 
Access i s provi ded af ter a proposal  has been approved by  an independent review committee 
ident ified for this purpose and after receipt of a signed data shari ng agreem ent. Data and 
docum ents, including the study  protocol , statistical analysis plan, clinical study  report, bl ank,or 
annotated case report forms, will be provided in a secure data sharing environment for up to 2 
years per proposal. 
CONFIDENTIAL I8B-MC-ITSZ (b)
59For details on s ubmi tting a request, see the instructions provided at 
www. clnicalstudy datarequest .com . 
10.1.6. Data Quality Assurance
All participant data relat ing to the study  will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee electronic ally ( for example , laboratory  
data). The investigator is responsible for verifying that data entries are accurate and 
correct by  physically or electronically signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect a ccess to source data documents.
Moni toring details describing strategy  (for example , risk-based init iatives in operations 
and qualit y such as Risk Management and Mit igation Strategies and Analyt ical Risk -
Based Monitoring), methods, responsibilit ies and requirements, including handling of 
nonco mpliance issues and monitoring techniques are pr ovided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  includin g 
qualit y checking of the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals ( for 
example , Contract Researc h Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and verifiable 
from source docum ents; that the safet y and ri ghts of  parti cipants a re being protected; and 
that the study  is being conducted in accordance wit h the current ly approved protocol and 
any other study  agreements, ICH GCP, and all applicable regu latory  requi rements.
Records and documents, including signed ICFs, pertaining to th e conduct of this study  
must be retained by the invest igator for the peri od outlined in the Clinical Trial 
Agreement (CTA) unless local regulat ions or institutional po licies require a longer 
retenti on peri od. No records m ay be destroy ed during the retentio n peri od wi thout the 
written approval  of the sponsor. No records may be transferred to another locat ion or 
party  without wri tten notificat ion to the sponsor .
In addit ion, Sponsor or its representati ves will periodi cally check a sample of the 
participant data recorded against source documents at the study  site. The study  may be 
audited by  Sponsor or its representatives, and/or regulatory  agencies at any  time. 
Invest igators will be given noti ce before an audit occurs.
CONFIDENTIAL I8B-MC-ITSZ (b)
60Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor. 
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data. The invest igator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considere d source and for the confirmat ion that data reported are 
accurate and complete by  signing the CRF .
Data collected via the sponsor- provided data capture system will be stored at a single third-party . 
The invest igator will have cont inuous access to the data during the study and unt il 
decommissio ning of the data capture sy stem .Before decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored el ectroni cally  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention. Data will subsequent ly be transferred fro m the central  vendor to the Sponsor data 
warehouse.
Data from co mplaint forms submitted to Sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained. The invest igator may need to request previous medical records or transfer 
records, depending on the study . Also, current m edical records must be available.
Definit ionof what consti tutes source data can be found in Section10.1.6.
10.1.8. Study and Site and Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will  be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable caus e 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to com ply with the protocol , the requi rements of the IRB/IEC 
or local health authori ties, the sponsor ’s procedures, or GCP guidelines
CONFIDENTIAL I8B-MC-ITSZ (b)
61Inadequate recruit mentof parti cipants by  the investi gator
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
Invest igators, the IECs/IRBs, the regulatory authorit ies, and any contract research 
organi zation(s) used in the study  of the reason for terminat ion or suspensio n, as spe cified by  the 
applicable regulatory  requi rements . The Invest igator shall pro mptly inform the participant and 
shoul d assure appropri ate participant therapy  and/or fo llow-up .
10.1.9. Publication Policy
In accordance with the sponsor’s publication po licy the results of this study  will be submi tted f or 
publicat ion by a peer -reviewed journal if the result s are deem ed to be of significant medical 
importance .
10.1.10. Investigator Information
Physicians with a specialt y inendocrinol ogy or primary  care physicians specializing in 
endocrino logy or internal medicine will participate as invest igators in this clinical trial.
CONFIDENTIAL I8B-MC-ITSZ (b)
6210.2. Appendix 2: Clinical Laboratory Tests
The tests detailed below will be performed by  the central  laboratory  except where indicated . 
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in Sect ion5
of the protocol. Addit ional tests may be performed at any t ime during the study as determined 
necessary  by the invest igator or required by local regulat ions. Invest igators must document their 
review of each laboratory  safet y report.
For the timing and frequency of the tests refer to the Schedule of Act ivities in Sect ion 1.3.
Clinical Laboratory Tests a
Hematology Clinical Chemistry (Serum Concentrations of)
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Total bilirubin
Mean cell volume Direct bilirubin
Mean cell hemoglobin concentration Alkaline phosphatase
Leukocytes (WBC) Chloride
Neutrophils, segmented Blood urea nitrogen (BUN)
Lymphocy tes Creatinine
Monocytes Glucose
Eosinophils Alanine aminotransferase (ALT)
Basophils Aspartate aminotransferase (AST)
Platelets Magnesium
Uric acid
Pregnancy Test (females only) b Total protein
Follicle -stimulating hormone c Albumin
Calcium
Urinalysis Creatine kinase (CK)
Specific gravity 1,5 Anhydroglucitol
pH Fructosamine
Protein
Glucose HbA1c
Ketones
Blood
Urine leukocyte esterase
Bilirubin
Nitri te
aAll laboratory tests will be assayed by a Lilly -designated central laboratory, unless otherwise noted.
bSerum pregnancy test must be performed in women of childbearing potential at Visit 1 followed by a urine 
pregnancy test within 24 hours before IP exposure at randomization and at other times at the investigator’s 
discretio n.
cFollicle -stimulating hormone test must be performed at Visit 1 for women at least 40 years of age with an intact 
uterus, not on hormone therapy, and who has had cessation of menses for at least 1 year without an alternative 
medical cause .
CONFIDENTIAL I8B-MC-ITSZ (b)
6310.2.1. Hypersensitivity Clinical Laboratory Tests
Laboratory testing shoul d be perform ed at the time of a Systemic Hy persensi tivity Event. 
Important inform ation about why , when, and what to test for are provided as fo llows. The 
management of the AEmay warrant lab oratory testing beyo nd that described belo w and shoul d 
be perform ed as clinically  indicated.
Laboratory  testing during a Sy stemic Hypersensit ivity Event is not perform ed for diagnostic 
purposes. Its intent is several fo ld:
To hel p characteri ze and cl assify  systemic hypersensit ivity reacti ons
To m eet regulatory  expectati ons
To improve subsequent clinical management by  helping to di stinguish between the 
various mechanist ic bases of anaphylaxis
When should labs be obtained?
In the presence of generalized urticaria or if anaphylaxis is suspected
After the subject has been stabilized, obtain a sample within 1 to 2 hours of the event ;
however, samples may  be obtained as late as 12 hours after the event as analy tes can 
remain altered for an extended period of time. Record the time at which the sample was 
collected.
Obtain a fo llow-up sam ple at the next regularly scheduled visit or after 4 weeks, 
whichever i s later.
What l abs* shoul d be obtained?
Tryptase**
ADA and LY concentration (PK)
oADA testing should include drug- specific immunoglobulin E ( IgE)or the 
basophil act ivation test (BAT)#. These tests are not routinely available and need 
to be developed for individual molecules based on their evo lving safet y profile. 
Samples are collected, and testing conducted once the assay  is available, as 
appropriate. Plea se consult an immuno logist wi thin GPS for further guidance.
Com plement
oC3, C3a,and C5a
Cytokines
oInterl eukin ( IL)‐6, IL‐1 β, IL‐10 (or any cytokine panel that includes these 
3cytokines)
* T hese lab oratori esare bundled in the Clinical Laboratory  Operat ions Hypersensit ivity 
Lab Testing Kit 
**If a try ptase sample is obtained more than 2 hours after the event ( that is,within 2 to 
12hours), or is not ob tained because more than 12 hours have lapsed since the event, obtain 
urine for N-methylhistamine (NMH) testing. Note that for try ptase serum  samples obtained 
within 2 to 12 hours of the event, urine NMH testing is performed in addit ion to try ptase 
testing. Co llect the first vo id urine fo llowing the event. Obta in a fo llow-up urine for NMH 
testing at the next regularly scheduled visit or after 4 weeks, whichever is later.
CONFIDENTIAL I8B-MC-ITSZ (b)
64#The BAT i s an in vitro cell based assay  that only  requi res a serum  sample. It i s a 
surrogate assay  for drug -specific IgE but is not specific for IgE.
CONFIDENTIAL I8B-MC-ITSZ (b)
6510.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: Therefore, an AE can be any unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments ( that is, ECG, radi ological scans, and vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the invest igator ( that is, not rel ated 
to progression of underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present b efore the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will n ot be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.
“Lack of efficacy ”or “failure of expected pharmacological act ion”per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae result ing fro m lack of efficacy 
will be reported as AE or SAE if they f ulfillthe definit ion of an AE or SAE.
The signs, symptoms, and/or clinical sequelae result ing from lack of efficacy will be 
reported as AE or SAE if they  fulfillthe defini tion of  an AE or SAE. Al so, “lack o f 
efficacy ” or “ failure of expected pharmaco logical acti on”also consti tutes an AE or 
SAE.
CONFIDENTIAL I8B-MC-ITSZ (b)
66Events NOT Meeting the AE D efinition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.Such a 
finding includes an episode considered to be related to hy poglycemia categori zed as 
either level 1 or l evel 2 based on plasma glucose levels.
oLevel 1: <70 m g/dL (3.9 mm ol/L) and glucose ≥54 mg/dL (3.0 mmo l/L)
oLevel 2: <54 m g/dL (3.0 mm ol/L)
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure ( for example , endoscopy  and appendectomy): the 
condi tion that l eads to the procedure is the AE.
Situations in which an untow ard m edical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
Ifan event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met ( for example , hospi talizat ion for signs/symptom s of the disease under study , death due to 
progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a. Is categorized as level 3 hypoglycemia: a severe event characterized by altered 
mental and/or physical status requiring assistance
b.Results in death
c.Is life -threatening
The term  ‘life-threatening’ in the definit ion of ‘serious ’refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
d.Requires inpatient hospitalizat ion or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal
for observat ion and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Com plicat ions that occur during hospitalization 
are AEs. If a complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, 
the event is serious. When in doubt as to whether ‘hospi talizati on’occurred or was 
necessary , the AE shoul d be cons idered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen 
from baseline is not considered an AE.
CONFIDENTIAL I8B-MC-ITSZ (b)
67e.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abil ity to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, 
and accidental trauma ( for example , sprained ankle) ,which may interfere wit h or 
prevent every day life f unctions but do not constitute a substant ial disruption .
f.Is a congenital anomaly/birth defect
g.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropri ate in other si tuations such as important medical events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the oth er 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or
convulsio ns that do not result in hospitalizat ion, or development of drug dependency or 
drug abuse .
10.3.3. Recording and Follow -up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entation (for example , hospi tal progress notes, l aboratory  reports, and 
diagnosti cs reports) rel ated to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF.
It is notacceptable for the invest igator to send photocopies of the participants ’
medical records to Sponsor or designee in lieu of com pletion of the AE/SAE CRF 
page.
There m ay be instances when copies of medical records for certain cases are requested 
by Sponsor or desi gnee . In thi s case, all part icipant identifiers, with the exception o f 
the participant number, will be redacted on the copies of the medical records before 
submissio n to Sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE .
CONFIDENTIAL I8B-MC-ITSZ (b)
68Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to oneof the fo llowing categori es:
Mild: An event that is easily tolerated by the participant, causing minimal disco mfort 
and not interfering with everyday act ivities.
Moderate: An event that causes sufficient discomfort and interferes wit h norm al 
everyday act ivities.
Severe: An event that prevents normal every day activi ties. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category  utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as ‘severe. ’
Assessment of Causality
Theinvest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
A ‘reasonable possibilit y’of a rel ationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rat her than a relat ionship cannot be 
ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the IB and/or Product Information, for marketed 
products, in his or her assessment.
For each AE/SAE, the invest igator must document in th e medical  notes that he or she 
has reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to Sponsor or designee . However, it 
is very important that the investigator always make an assessment of causalit y for 
every event before the init ial transmissio n of the SAE data to Sponsor or designee .
The invest igator may change his or her opinion o f causalit y in light of follow -up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting requirements.
CONFIDENTIAL I8B-MC-ITSZ (b)
69Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by Sponsor or 
designee to elucidate the nature and/or causalit y of the AE or SAE as fully as possible . 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
New or updated informat ion will be recorded in the originally co mpleted CRF.
The invest igator will submi t any  updated SAE data to Sponsor or designee within 24 
hours of receipt of the informat ion.
10.3.4. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collect ion 
tool.
If the electronic system is unavailable, then the site will use the paper SAE data 
collect ion tool  (see next secti on) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken offline to prevent the entry  of new data or changes to exist ing data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken offline, then the site can report this informat ion on a paper SAE form (see next 
section) or to Lilly Medical by tel ephone.
Contacts for SAE reporting can be found at 1.800.LillyRx .
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to Lilly Medical.
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found at 1.800.LillyRx .
CONFIDENTIAL I8B-MC-ITSZ (b)
7010.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions
Women of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile . If fertility is unclear ( for exampl e, amenorrhea in adolescents or athl etes) 
and a menstrual cyclecannot be confirmed before first dose of study  intervent ion, addi tional 
evaluat ion shoul d be considered.
Women notof childbearing potential 
1.Prem enarchal
2.Prem enopausal female with oneof the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
For individuals withperm anent infert ility due to an alternate medical cause other than the 
above, ( for example , Mullerian agenesis and androgen insensit ivity), invest igator 
discreti on shoul d be applied to determining stud y entry .
Note: Documentation can come fro m thesite personnel’s review of the participant’s 
medical records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female is defined as, women with:
12 m onths am enorrhea for wom en aged >55years , with no need for follicle 
stimulat ing hormone (FSH)
12 m onths of amenorrhea for women >40 y ears old wi th FSH ≥40 m IU/mL and 
no other m edical condit ion such as anorexia nervosa and not taking medicat ions 
during the amenorrhea ( for example, oral contraceptiv es, horm ones, 
gonadotropin -releasing horm one, ant i-estrogens, sel ective estrogen receptor 
modulators, or chemotherapy  that induced amenorrhea)
Contraception Guidance
Male Participants
No m ale contraception required .
Female Participants
A female part icipant is eligible to participate if she is not pregnant, intending to beco me 
pregnant, or breastfeeding, and at least one of the following con ditions applies:
Is not a woman of childbearing potential
OR
Is a WOBCP with the fo llowing study  requi rements:
A WOCBP m ust test negative for pregnancy prior to init iation of treatment as 
indicated by  a negat ive serum pregnancy test at the screening visit followed by a 
CONFIDENTIAL I8B-MC-ITSZ (b)
71negat ive urine pregnancy text within 24 hours prior to exposure to invest igational 
product (IP) at Visit 3.
WOCBP who are abst inent (if this is co mplete abstinence, as their preferred and 
usual lifest yle) or in a same -sex relat ionship (as part of their preferred and usual 
lifest yle) must agree to either remain abstinent or stay in a sam e-sex rel ationship 
without sexual relat ionships wi th males. Peri odic abst inence (e.g., calendar, 
ovulation, symptothermal, post -ovulation methods), declarat ion of  abst inence just 
for the durati on of  a trial, and wi thdrawal are not acceptable methods of 
contracepti on.
WOCBP (who are not abst inent or in a same -sex rel ationship) must agree t o use 
one highly effect ive method (l ess than 1% failure rate) of contrace ption, or a 
combinat ion of two effect ive methods of contraception for the ent irety of the 
study .
CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDE :
Highly effective methods of contraception 
Combined oral contraceptive pill and mini -pill
NuvaRing
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena® and ParaGard)
Contraceptive patch – ONLY women <198 pounds or 90Kg
Total  Abstinence
Vasectomy
Fallopian tube implants (Essure) [if confirmed by hysterosalpingogram]
Effective methods of contraception (must use two forms combined)a
Male condom wit h spermicideb
Female condo m withspermicideb
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicide
aParticipants may choose to use a double -barrier method of contraception. Barrier protection methods without 
concomitant use of a spermicide are not a reliable or acce ptable method. Thus, each barrier method must include 
use of a spermicide.
bMale and female condoms should not be used in combination as a double barrier method due to the high failure 
rate when these methods are combined.
CONFIDENTIAL I8B-MC-ITSZ (b)
72Collection of Pregnancy Information
Female Participants Who Become Pregnant
The invest igator will co llect pregnancy information on any female participant who 
beco mes pregnant while participat ing in this study . The init ial informat ion will be 
recorded on the appropriate form and submitted to the sponsor within 24 hours of 
learning of a parti cipant ’s pregnancy .
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neonate and the 
inform ation will be forwarded to the sponsor. Generally , follow-up will not be requi red 
for longer than 6 to 8 weeks bey ond the estimated delivery  date. Any  terminat ion of 
pregnancy will be reported, regardless of gestati onal age, fetal status (presence or absence 
of anomalies) or indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for m edical  reasons will be reported 
as an AE or SAE. 
A spontaneous abortion (occurring at <20 weeks gestational age) or still birth (occurring 
at >2 0weeks gestational age) is always considered to be an SAE and will be reported as 
such. 
Any post -study pregnancy related SAE consi dered reasonably related to the study  
intervent ion by the investigator will be reported to the sponsor as described in 
Secti on10.3.4 . While the invest igator is not obligated to actively seek this informat ion in 
former study  parti cipants, he or she may learn of an SAE through spontaneous reporting.
Any female participant who becomes pregnant while participat ing in the study will 
discontinue fro m study  intervent ionand from  the study .
CONFIDENTIAL I8B-MC-ITSZ (b)
7310.5. Appendix 5: Hepatic Safety: Suggested Actions and Follow -up 
Assessme nts 
Close Hepatic Monitoring
Laboratory  tests including ALT, AST, ALP, TBL, D. Bil, GGT, and CK , shoul d be repeated 
within 48 to 72 hours to confirm the abnormalit y and to determine if it is increasing or 
decreasing, if one or more of these condit ions occur . 
If a participant with baseline 
resul ts of ... Develops the following elevat ions:
ALT or AST <1.5x ULN ALT or AST ≥3x ULN
ALP <1.5x ULN ALP ≥2x ULN
TBL <1.5x ULN TBL ≥2x ULN (except for pa rticipants with Gilbert’s syndrome)
ALT or AST ≥1.5x ULN ALT or AST ≥2x baseline
ALP ≥1.5x ULN ALP ≥2x baseline
TBL ≥1.5x ULNTBL ≥2x baseline (except for pa rticipants with Gilbert’s 
syndro me)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for 
possible causes of abnorm al liver tests shoul d be ini tiated by  the invest igator in consultat ion with 
the Lilly -designated m edical mo nitor. At a minimum, this evaluat ion shoul d include physical 
examinat ion and a thorough medical history , including symptom s, recent illnesses ( for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history  of concomi tant 
medicat ions (including over -the-counter), herbal and dietary  supplements, history  of alcoho l 
drinking and other substance abuse.
Initially, monitoring o f symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemical tests. 
Subsequently, the frequency  of monitoring m ay be l owered to once every  1to 2 weeks, if the 
participant’s clinical condit ion and l ab resul ts stabilize. Moni toring of ALT, AST, ALP, and 
TBL should cont inue unt il levels normalize or return to approximate baseline levels.
CONFIDENTIAL I8B-MC-ITSZ (b)
74Comprehensive Hepatic Evaluation
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of these condit ions occur:
If a participant with baseline 
resul ts of... Develops the following elevat ions:
ALT or AST <1.5x ULN ALT or AST ≥3x ULN with hepatic signs/symptoms ,* or
ALT or AST ≥5x ULN
ALP <1.5x ULN ALP ≥3x ULN
TBL <1.5x ULN TBL ≥2x ULN (except for pa rticipants with Gilbert’s 
syndro me)
ALT or AST ≥1.5x ULN ALT or AST ≥2x baseline wit h hepat ic signs/symptoms ,* or
ALT or AST ≥3x baseline
ALP ≥1.5x ULN ALP ≥2x baseline
TBL ≥1.5x ULN TBL ≥1.5x baseline (except for pa rticipants with Gilbert’s 
syndro me) 
*Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, 
rash, and/or eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for PT-INR; tests for viral hepat itis A, B, C, or E; tests 
for autoimmune hepatit is; and an abdominal imaging study  (for example, ultrasound or CT scan). 
Based on the pa rticipa nt’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus 
(HDV ), cytomegalovirus (CMV ), Eps tein-Barr vi rus (EBV), acetaminophen levels, 
acetaminophen protein adducts, urine toxico logy screen, Wilso n’s disease, blood alcoho l levels, 
urinary  ethyl  glucuronide, and serum phosphat idylethano l. Based on the circumstances and the 
investigator’s assessm ent of the parti cipant’s clinical condit ion, the investigator should consider 
referring the participant for a hepatologist or gastroenterologist consultation, magnet ic resonance 
cholangiopancreatography  (MRCP), endoscopi c retrograde cholangiopancreatograph y (ERCP), 
cardi ac echocardi ogram , or a liver biopsy.
Additional hepatic data collection in study participants who have abnormal liver tests 
during the study
Addit ional hepatic safet y data collect ion in hepat ic safet y case report forms (CRF) should be 
perfo rmed in study  parti cipants who meet oneor more of the following 5 condit ions:
1.Elevat ion of serum ALT to ≥5x ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5x ULN)
In parti cipants wi th baseline ALT ≥1.5x ULN, the thresho ld is ALT ≥3x baseline
on 2 or more consecutive tests
2.Elevated TBL to ≥2xULN (if baseline TBL <1.5x ULN) (except for cases of known 
Gilbert’s syndrome)
CONFIDENTIAL I8B-MC-ITSZ (b)
75In parti cipants wi th baseline TBL ≥1.5x ULN, the thresho ld should be TBL ≥2x 
baseline
3.Elevat ion of serum ALP to ≥2x ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN)
In parti cipants wi th baseline ALP ≥1.5x ULN, the thresho ld is ALP ≥2x baseline 
on 2 or more consecutive blood tests
4.Hepati c event consi dered to be a seri ous adverse event (SAE)
5.Discontinuati on of  study  drug due to a hepati c event 
Note: the interval between the two consecutive blo od tests should be at least 2 day s.
10.5.1. Hepatic Evaluation Testing
If the invest igator has confirmed liver test abn ormality, he or she shoul d select further
appropriate tests. For the selected testing, analysis is required to be completed by  the Lilly  
designated central laboratory  except for microbio logy.
Local  testing m ay be performed in addit ion to central testing when requi red for immediate 
participant management.
Results will be reported if a validated test or calculation is available.
CONFIDENTIAL I8B-MC-ITSZ (b)
76Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -Red Blood Cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -White Blood Cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
    Neutrophils, segmented Gamma -glutamyl transferase (GGT)
    Lymphocytes Creatine kinase (CK)
    Monocytes Other Chemistry  
    Basophils Acetaminophen
    Eosinophils Acetaminophen Protein Adducts
Platelets Alkaline Phosphatase Isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl Alcohol (EtOH)
Prothrombin Time, INR (PT -INR) Haptoglobin
Serology Immunoglobulin IgA (Quantitative)
Hepatitis A Virus (HAV) Testing: Immunoglobulin IgG (Quantitative)
    HAV Total Antibody Immunoglobulin IgM (Quantitative)
    HAV IgM Antibody Phosphatidylethanol (PEth)
Hepatis B Virus (HBV) Testing: Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug Screen
    Hepatitis B surface antibody (Anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (Anti -HBc) Other Serology
    Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
    Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
    HBV DNA dAnti- actin antibody b
Hepatis C Virus (HCV) Testing: Epstein -Barr Virus (EBV) Testing:
    HCV antibody     EBV antibody
    HCV RNA d    EBV DNA d
Hepatitis D Virus (HDV) Testing: Cytomegalovirus (CMV) Testing:
    HDV antibody     CMV antibody
Hepatitis E Virus (HEV) Testing:     CMV DNA d
    HEV IgG antibody Herpes Simplex Virus (HSV) Testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody
    HEV RNA d    HSV (Type 1 and 2) DNA d
Microbiology cLiver Kidney Microsomal Type 1 (LKM -1) Antibody
Culture:
    Blood
    Urine
aThis is not required if Anti -Actin Antibody is tested.
bThis is not required if Anti -smooth muscle antibody (ASMA) is tested.
cAssay ed by Investigator-designated local laboratory ONLY; no Central Testing available.
dReflex/confirmation dependent on regulatory requirements and/or testing availability.
CONFIDENTIAL I8B-MC-ITSZ (b)
7710.6. Appen dix 9: Abbreviations
Term Definition
AACE American Association of Clinical Endocrinologists
ADA Anti-drug Antibodies
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransferase
BAT basophil activation test
CF Correction Factor
CFR Code of Federal Regulations
CGM continuous glucose monitoring
CIOMS Council forInternational Organizations ofMedical Sciences
CK creatine kinase
CMV cytomegalovirus
complaint A complaint is any written, electro nic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -relate d, good clinical practice (GCP), and applicable regulatory 
requirements.
CRP clinical research physician: Individual responsible for the medical conduct of the 
study. Responsibilities of the CRP may be performed by a physician, clinical research 
scientist , global safety physician or other medical officer.
CT computed tomography
D. Bill direct bilirubin
Device Deficiencies Equivalent to product complaint
DIA Duration of Insulin Action
DMC data monitoring committee
EBV Epstein -Barr virus
CONFIDENTIAL I8B-MC-ITSZ (b)
78ECG electrocardiogram
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form d irectly 
or through their legally acceptable representatives.
ERCP endoscopic retrograde cholangiopancreatography
FSH follicle stimulating hormone
GCP good clinical practice
gestational age The estimated age of the fetus calculated from the first day of the last menstrual period 
to the delivery of the fetus. It is expressed in the number of completed weeks. This is 
based on 40 weeks or 10 months .
GGT Gamma -glutamyltransferase
GLP-1 glucagon -like peptide 1
HCP health care professional
HDV Hepatitis D virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
ICR insulin -to-carboh ydrate ratio
IEC Independent Ethics Committees
IgE immunoglobulin E
IL interleukin
IMP Investigational Medicinal Product
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Infor med consent is 
documented by means of a written, signed and dated informed consent form .
INR international normalized ratio
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment 
groups, that is conducted before the final reporting database is created/locked.
CONFIDENTIAL I8B-MC-ITSZ (b)
79investigational 
product (IP)A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB Institutio nal Review Boards
ISF insulin sensitivity factor
ITT intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant (that is, 
the planned treatment regimen) rather than the actual treatment given. It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to 
the planned course of treatment.
IV intravenous
IWRS interactive web -response sy stem
MedDRA Medical Dictionary for Regulatory Activities
MDI multiple daily injections
MMA mobile medical app
MMRM mixed model repeated measures
MRCP magnetic resonance cholangiopancreatography
NAFLD non-alcoholic fatty liver disease
NIMP Non-investigational Medicinal Product
NMH N-methy lhistamine
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as re cipient of an investigational medicinal product or as a control
PIs primary  investigators 
PK/PD pharmacokinetics/pharmacodynamics
PT prothrombin time
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
Screen The act of determining if an individual meets minimum requirements to become part 
of a pool of potential candidates for participation in a clinical study. 
CONFIDENTIAL I8B-MC-ITSZ (b)
80SMS Study management suite
T1D type 1 diabetes
T2D type 2 diabetes
TBL total bilirubin
TBD Total Basal Dose
TDD Total Daily Dose
TEAE Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens 
relative to the pretreatment state, and does not neces sarily  have to have a causal 
relatio nship with this treatment.
ULN upper limit of normal
USPI United States Prescribing Information
WOCBP woman of childbearing potential
CONFIDENTIAL I8B-MC-ITSZ (b)
8110.7. Appendix 10: Protocol Amendment History
Amendment [a] 
Overall Rationale for the Amendment:
Section # and Name Description of Change Brief Rationale
1.3 Schedule of 
Activities (SoA)Removal of Visi t 7 for 
investigat ional product (IP) 
dispensingStudy  IP will not be dispensed at 
Visit 7. IP will be dispensed at Visit s 
3 and 11. 
1.3. Schedule of 
Activities (SoA), 4.1.1. 
Study  Visi tsAddit ionof language to 
clarify data capture on insulin 
dosingClarificat ion for transcribing data 
into eCRF for insulin dosing at Visit 
3 and Visit 14
5.1. Inclusio n Cri teria Addit ion oflanguage to align 
withLilly  guidanceClarificat ion of inclusio n criteria for 
females regarding pregnancy, 
breast feeding and contraceptive 
guidance 
9.4.1. General 
ConsiderationsAdd analysis details if mixed 
model repeated m easures 
(MMRM) does not convergeClarificat ion of analysis details if 
MMRM does not converge
Addit ion of language for 
continuous glucose 
monitoring (CGM) data 
analysis for Visit 3 and 
Visit 14Clarificat ion of study  intervent ions 
data during study  periods
9.4.2. Primary 
Endpoint(s)Replace analysis method with 
analysis of covariance 
(ANCOVA)Change was made because CGM 
data will only be derived for Visit 3 
and Visit 14
Addit ion of language for 
CGM data analysis for Visit 3 
and Visit 14Clarificat ion ofstudy  intervent ions 
data during study  periods
10.4. Appendix 4: 
Contraceptive Guidance 
and Co llection of 
Pregnancy InformationAddit ion of language to align 
with Lilly  guidanceClarificat ion of contracept ive 
guidance 
Throughout Minor edi torial and docum ent 
formatting revisi onsThese are minor changes; therefore, 
they have not been summarized
CONFIDENTIAL I8B-MC-ITSZ (b)
8211. References
Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanovič L, Roberts VL, 
Rodbard D, Tamborl aneWV, Walsh J.American Associat ion of Clinical Endocrino logists and 
American Co llege of Endocrino logy 2016 Outpatient Gl ucose Moni toring Consensus Statement. 
Endocrine Practice . 2016 ; 22(2): 231-261. 
Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM. Ultra Rapid Lispro (URLi) Improves 
Postprandi al Glucose (PPG) Con trol vs. Hum alog (Lispro) in Patients wi th Type 2 Di abetes 
(T2D): PRONTO -T2D [abstract]. In: American Diabetes Association 4 June 2019; 68(1).
BodeBW. Insulin pump therapy in Therapy for Diabetes Mellitus and related disorders , Fourth 
edition. In: Lebovitz HE, editor. American Diabetes Associat ion; 2004.
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type1and ty pe 2 di abetes. JAMA . 
2003;289 :2254 -2264.
Gan MJ, Albanese -O’Neill A, Haller MJ. Ty pe 1 diabetes: current concepts in epidemio logy, 
pathophysio logy, clinical  care, and research. Curr Probl Pediatr Adolesc Health Care . 
2012 ;42(10):269 -291
Insulin pump therapy  and cont inuous glucose monitoring. Pi ckup J, edi tor. L ondon: Oxford 
Universit y Press; 2009.
King AB, Armstrong DU. A prospective evaluat ion of insulin dosing recommendat ions in 
patients wi th type 1 diabetes at near normal glucose control: basal dosing. J Diabetes Sci 
Technol . 2007a;1(1):42 -46.
King AB, Armstrong DU. A prospective evaluat ion of insulin dosing recommendat ions in 
patients wi th Type 1 Di abetes at near normal glucose control: bolus dosing. J Diabetes Sci 
Technol . 2007 b;1(1):42 -46.
Allen King. How Much Do I Give? Reeva luation of Insulin Dosing Estimat ion Form ulas Using 
Continuous Glucose Monitoring. Endocrine Practice . 2010;16(3):428 -432.
King AB . Continuous glucose m onitoring -guided insulin dosing in pump -treated pati ents wi th 
type 1 di abetes: a clinical guide . J Diabetes Sci Technol . 2012;16(3):191 -203.
Klaff L, Cao D, Dellva MA, Tobian J, Miura J, Dahl D, Bue -Valleskey  JM. Ul tra Rapi d Lispro 
(URLi) Improves Postprandial Glucose (PPG) Control  vs. Humalog (Lispro) in T1D: PRONTO 
T1D Study  [abstract]. In: American D iabetes Associat ion;4 June 2019; 68(1).
Kruszynska YT, Hom e PD, Hanning I, Albert i KGMM. Basal and 24- hour C -peptide and insulin 
secretion rate in normal man. Diabetologia. 1987;30:16-21.
Kuroda A, Yasuda T, Takahara M, Sakamoto F, Kasami R, Miyashita K, Yoshida S, Kondo E, 
Aihara K, Endon I, Matsuoka T, Kaneto H, Matsumoto T, Shimo mura I, Matsuhisa M. 300–400 
Divided by  total daily insulin dose in t ype 1 diabetes patients who use the insulin pump . 
Diabetes Technol Ther . 2012;14(11):1077- 1080.
Polonsk y KS, Given BD, Van Cauter E. Twenty- four-hour profiles and pulsat ile patterns of 
insulin secret ion in normal and obese subjects. J Clin Invest . 1988;81:442-448.
CONFIDENTIAL I8B-MC-ITSZ (b)
83Stark -Casagrande S, Fradkin JE, Say dah SH, Rust KF, Cowie CC. The prevalence of meet ing 
A1C, b lood pressure, and LDL goals amo ng people with diabetes, 1988 -2010. Diabetes Care . 
2013;36(8):2271 -2279 .
Tresiba [package insert]. DK -2880 Bagsvaerd, Denmark, Novo Nordisk A/S; 2015.
Leo Document ID = 3dbe4b3d-88ac-475e-bbbb-827b6db38ce9
Approver: 
Approval Date & Time: 24-Nov-2020 13:51:42 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 24-Nov-2020 14:04:12 GMT
Signature meaning: Approved
PPD
PPD